


RL: BIOL (Biological study)
(of blood plasma and aorta, in **atherosclerosis**, aspirin and
dipyridamole effect on)

L7 ANSWER 193 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1979:413847 CAPLUS
DN 91:13847
TI Aspirin inhibits development of coronary **atherosclerosis** in
cynomolgus monkeys (*Macaca fascicularis*) fed an atherogenic diet
AU Pick, Ruth; Chediak, Juan; Glick, Gerald
CS Cardiovasc. Inst., Michael Reese Hosp., Chicago, IL, 60616, USA
SO Journal of Clinical Investigation (1979), 63(1), 158-62
CODEN: JCINAO; ISSN: 0021-9738
DT Journal
LA English
CC 1-5 (Pharmacodynamics)
GI



AB In monkeys fed an atherogenic diet, aspirin (I) [50-78-2] (81
mg/monkey/day) did not affect plasma cholesterol [57-88-5] levels or
aortic **atherosclerosis**. Platelet aggregation induced by
arachidonic acid was almost completely suppressed. I decreased
significantly the no. of coronary vessels with atherosclerotic involvement
and the no. of coronary vessels narrowed by 20% or more. Thus, I appears
to exert a protective effect in the primary prevention of diet-induced
coronary **atherosclerosis** in a primate model.
ST aspirin coronary **atherosclerosis** prevention
IT **Atherosclerosis**
(coronary, aspirin prevention of)
IT **50-78-2**
RL: BIOL (Biological study)
(coronary **atherosclerosis** prevention by)
IT 57-88-5, biological studies
RL: BIOL (Biological study)
(of blood plasma, aspirin effect on)

=> d his

(FILE 'HOME' ENTERED AT 10:19:37 ON 23 JAN 2003)

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 23 JAN 2003

E ASPRIN

E ASPIRIN

L1 50 S E3

E ATORVASTATIN

L2 8 S E2-E3

FILE 'CAPLUS' ENTERED AT 10:22:28 ON 23 JAN 2003

FILE 'REGISTRY' ENTERED AT 10:22:39 ON 23 JAN 2003

FILE 'CAPLUS' ENTERED AT 10:23:00 ON 23 JAN 2003

E ATHEROSCLEROSIS

L3 33649 S E3
 E ARTERIOSCLEROSIS
 L4 9906 S E1-E12
 L5 16388 S L1
 L6 725 S L2
 L7 202 S L5 AND L3
 L8 46 S L5 AND L4
 L9 29 S L8 NOT L7
 L10 39179 S L3 OR L4
 L11 143 S L10 AND L6

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG.Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	189.02	206.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.86	-5.86

STN INTERNATIONAL LOGOFF AT 10:50:20 ON 23 JAN 2003

higher ratio of unsatd.-to-satd. .beta.-steroids, and a markedly lower .beta.-steroid esterification; only the fraction A shows similar behavior to serum fraction A. Thus, it seems that while the lipid patterns of serum and of the atheromatous plaque are a common and simultaneous expression of a particular behavior of lipid metabolism, their relation is not well understood. Drugs given therapeutically change the pattern of serum lipids, but their effect on the atheromatous plaque is not known. The effect of the following drugs on the serum lipid pattern in **atherosclerosis** was noted: inositol, Na salicylate, vitamin E, nicotinic acid, 3-pyridylacetic acid, diphenesenic acid, and a heparinoid extd. from the duodenal mucosa. All the drugs, though generally having an hyposteroidemic effect, act on the serum lipid pattern in a different manner, thus showing specific and characteristic mechanisms of action for each of them. Of these drugs, only the heparinoid exerts a complete action on the hyperlipemic pattern of **atherosclerosis**, represented by a progressive rearrangement of the serum lipid pattern up to its normalization. The heparinoid is tolerated even at high doses, seems to have no side effects, improves tolerance to carbohydrates in lipopletoric diabetes, and decreases azotemia in uremic syndromes, which are often assocd. with **atherosclerosis**.

- IT Lipids
(blood-serum, in **atherosclerosis**, effect of heparinoid,
inositol, nicotinic acid, etc., on)
- IT Intestines
(heparinoid from mucosa of, effect on lipids in blood serum in
atherosclerosis)
- IT Glycerides
Phospholipids
(in blood serum, in **atherosclerosis**, effect of heparinoid,
inositol, etc., on)
- IT Steroids
(in blood serum, in **atherosclerosis**, effect of heparinoid,
inositol, nicotinic acid, etc., on)
- IT **Atherosclerosis**
(lipids in blood in, effect of heparinoid, inositol, nicotinic acid,
etc., on)
- IT Heparinoids and Heparinlike substances
(lipids in blood serum in response to, in **atherosclerosis**)
- IT Inositol
(lipids in blood serum in **atherosclerosis** and)
- IT 95040-85-0, 4-Hexenoic acid, 2-(4-biphenyl)-
(effect on lipids in blood serum in **atherosclerosis**)
- IT 57-88-5, Cholesterol
(in blood serum in **atherosclerosis**, effect of heparinoid,
inositol, nicotinic acid, etc., on)
- IT 54-21-7, Sodium salicylate 501-81-5, 3-Pyridineacetic acid
1406-18-4, Vitamin E
(lipids in blood serum in **atherosclerosis** in relation to)
- IT 59-67-6, Nicotinic acid
(lipids in blood serum in response to, in **atherosclerosis**)

L20 ANSWER 754 OF 800 CAPLUS COPYRIGHT 2002 ACS

AN 1986:147555 CAPLUS

DN 104:147555

TI Effects of vitamin C and E, trace element selenium and brown sugar in
guinea pig arteriosclerosis

AU Sun, Yuming; Lu, Tianluan; Gao, Jianzhong; Dou, Shulan; Wang, Hong; Sun,
Shuqin; Li, Tianyang; Sun, Rui

CS Peop. Rep. China

SO Tianjin Yiyao (1985), 13(10), 615-17

CODEN: TIYADG; ISSN: 0253-9896

DT Journal

LA Chinese
 CC 18-1 (Animal Nutrition)
 AB Dietary vitamin C [50-81-7] and E [1406-18-4], Se, and brown sugar decreased the incidence of arteriosclerosis induced by cholesterol (0.1 g/day) in guinea pig. In the exptl. animal diets, the supplementary amts. were 1.5 mg vitamin C, 1.5 mg vitamin E, 35 .mu.g Na2SeO3, and 2 g brown sugar/day/animal. Vitamin C showed the strongest effect on inhibition of arteriosclerosis. The extents of fatty liver and peroxy fatty acids were also decreased by the inhibitory agents.

ST **atherosclerosis** vitamin selenium sugar diet; liver lipid
atherosclerosis inhibitor diet

IT Lipids, biological studies
 RL: BIOL (Biological study)
 (dietary **atherosclerosis** inhibitors effect on, of liver)

IT **Atherosclerosis**
 (inhibition of, dietary vitamin C and E and brown sugar in)

IT Liver, composition
 (lipids and peroxy fatty acids of, dietary **atherosclerosis** inhibitors effect on)

IT Fatty acids, biological studies
 RL: BIOL (Biological study)
 (peroxy, dietary **atherosclerosis** inhibitors effect on, of liver)

IT 50-81-7, biological studies 1406-18-4 7782-49-2, biological studies
 RL: BIOL (Biological study)
 (**atherosclerosis** inhibition by dietary)

IT 57-50-1, biological studies
 RL: BIOL (Biological study)
 (brown, **atherosclerosis** inhibition by dietary)

=> s 118 415 all

MISSING OPERATOR L18 415

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d 118 415 all

L18 ANSWER 415 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1968:494978 CAPLUS

DN 69:94978

TI Inhibitory effect of papaverine hydrochloride and ascorbic acid on the development of experimental **atherosclerosis**

AU Bedzhanyan, Zh. S.; Martikyan, M. S.

CS Erevan. Klin. Bol. "Malat'ya", Erevan, USSR

SO Zh. Eksp. Klin. Med. (1968), 8(1), 35-42

CODEN: ZKMAAX

DT Journal

LA Russian

CC 15 (Pharmacodynamics)

AB Female albino rats were fed cholesterol (I) for 60 days. This caused an increase of I content in serum and an inhibition of the resorptive function of the reticuloendothelial system (RES). Overall serum proteins did not change; on paper electrophoresis, .alpha.- and .beta.-globulins increased, albumins decreased slightly, and .gamma.-globulins decreased strongly. Gradual return to normal or nearly normal values was observed during the subsequent 30 days. When papaverine, (II) or II plus ascorbic acid, was administered s.c. during this period, serum I decreased and the resorptive function of the RES and serum protein fractions became normal more rapidly. The addnl. effect of II plus ascorbic acid over that of II alone was esp. marked in case of serum I and the RES function.

ST papaverine cholesterol; cholesterol papaverine; **atherosclerosis**
papaverine; ascorbic acid papaverine; proteins serum papaverine
IT Reticulo-endothelial system
(ascorbic acid and papaverine effect on resorption by, in
atherosclerosis)
IT **Atherosclerosis**
(ascorbic acid and papaverine in treatment of)
IT Blood serum
(cholesterol in, in **atherosclerosis**, ascorbic acid and
papaverine effect on)
IT Globulins, blood serum
RL: BIOL (Biological study)
(in **atherosclerosis**, ascorbic acid and papaverine effect on)
IT 61-25-6
RL: BIOL (Biological study)
(**atherosclerosis** treatment with ascorbic acid and)
IT **50-81-7**, biological studies
RL: BIOL (Biological study)
(**atherosclerosis** treatment with papaverine and)
IT 57-88-5, biological studies
RL: BIOL (Biological study)
(in blood serum, in **atherosclerosis**, ascorbic acid and
papaverine effect on)

=>

DT Journal
LA Russian

L16 ANSWER 318 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:64777 CAPLUS

DN 70:64777

TI Reaction of the hypothalamo-hypophyseal neurosecretory system (HHNS) of dogs with experimental **atherosclerosis** in response to the administration of adrenaline

AU Bogdanovich, N. K.; Gannushkina, I. V.; Shafranova, V. P.

CS Inst. Morfol. Cheloveka, Moscow, USSR

SO Arkh. Patol. (1968), 30(12), 8-14

CODEN: ARPTAF

DT Journal

LA Russian

L16 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:55680 CAPLUS

DN 70:55680

TI Blood sugar content in rabbits in experimental **atherosclerosis** and coronary insufficiency provoked by immobilization

AU Tyavokin, V. V.

CS Leningrad. Pediat. Med. Inst., Leningrad, USSR

SO Byull. Eksp. Biol. Med. (1968), 66(12), 27-8

CODEN: BEBMAE

DT Journal

LA Russian

L16 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:54495 CAPLUS

DN 70:54495

TI Effect of adrenaline on the capacity of intact erythrocytes to raise the thromboplastin activity of plasma

AU Ashkinazi, I. Ya.

CS I. P. Pavlov Inst. Physiol., Leningrad, USSR

SO Byull. Eksp. Biol. Med. (1969), 67(1), 3-5

CODEN: BEBMAE

DT Journal

LA Russian

L16 ANSWER 321 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:45641 CAPLUS

DN 70:45641

TI Participation of catechol amines in the development of experimental **atherosclerosis**

AU Amiredzhibi, R. O.

CS Inst. Klin. Eksp. Kardiol. im. Tsinamdzgvrishvili, Tbilisi, USSR

SO Soobshch. Akad. Nauk Gruz. SSR (1968), 51(2), 395-400

CODEN: SAKNAH

DT Journal

LA Russian

L16 ANSWER 322 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1968:112878 CAPLUS

DN 68:112878

TI Catechol amines in [human body] fluids

AU Ciplea, Al.; Bubuianu, Gh.; Dragulescu, N.

CS Akad. Soz. Repub. Rumaenien, Bucharest, Rom.

SO Rev. Roum. Physiol. (1967), 4(4), 267-73

CODEN: RRPFAU

DT Journal

LA German

L16 ANSWER 323 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1967:507057 CAPLUS
DN 67:107057
TI Influence of monoamine oxidase inhibitors on platelet adhesiveness
AU Mandecki, Tadeusz
CS Silesian Med. Acad., Katowice, Poland
SO Acta Med. Pol. (1967), 8(2), 219-37
CODEN: AMDPAA
DT Journal
LA English

L16 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1967:461248 CAPLUS
DN 67:61248
TI Experimental **atherosclerosis**. Effect of adrenaline
AU Nityanand, Swarn
CS Div. Exptl. Med., Central Drug Res. Inst., Lucknow, India
SO Indian J. Exp. Biol. (1967), 5(2), 87-90
CODEN: IJEBA6
DT Journal
LA English

L16 ANSWER 325 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1967:450796 CAPLUS
DN 67:50796
TI Effects of adrenaline and of smoking in patients with peripheral
atherosclerotic vascular disease
AU Kingsbury, Kenneth J.; Jarrett, R. John
CS St. Mary's Hosp., London, UK
SO Lancet (1967), II(7505), 22-3
CODEN: LANCAO
DT Journal
LA English

L16 ANSWER 326 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1967:430665 CAPLUS
DN 67:30665
TI Indexes of metabolic processes in rabbit cerebral hemispheres in
experimental **atherosclerosis**
AU Pogodaev, K. I.; Turova, N. F.
CS Second N. I, Pirogov Med. Inst., Moscow, USSR
SO Ukr. Biokhim. Zh. (1946-1977) (1967), 39(1), 29-33
CODEN: UBZHAZ
DT Journal
LA Russian

L16 ANSWER 327 OF 327 CAPLUS COPYRIGHT 2002 ACS
AN 1967:429557 CAPLUS
DN 67:29557
TI Atherosclerotic lesions in the vessels of rabbits in conditions of
disturbed hormonal regulation of water-salt metabolism
AU Panin, L. E.
CS Tomsk. Med. Inst., Tomsk, USSR
SO Arkh. Patol. (1967), 29(4), 47-50
CODEN: ARPTAF
DT Journal
LA Russian

=> s 15

L17 49222 L5

=> s 117 and 110

L18 420 L17 AND L10

=> d 118 370-420

L18 ANSWER 370 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1977:103474 CAPLUS

DN 86:103474

TI Vitamin C and cholesterol metabolism

AU Thiele, O. W.

CS Goettingen, Ger.

SO Hippokrates (1974), 45(3), 383-5

CODEN: HIPPAH

DT Journal; General Review

LA German

L18 ANSWER 371 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1977:87251 CAPLUS

DN 86:87251

TI Change in the level of vitamin C in the blood in ischemic heart disease in relation to complex treatment

AU Mirveisova, G. I.

CS Azerb. Med. Inst. im. Narimanova, Baku, USSR

SO Azerb. Med. Zh. (1976), 53(11), 55-6

CODEN: AZMZA6

DT Journal

LA Russian

L18 ANSWER 372 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1977:50648 CAPLUS

DN 86:50648

TI L-Ascorbic acid, L-ascorbate 2-sulfate, and atherogenesis

AU Finamore, F. J.; Feldman, Rose P.; Cosgrove, G. E.

CS Biol. Div., Oak Ridge Natl. Lab., Oak Ridge, Tenn., USA

SO Int. J. Vitam. Nutr. Res. (1976), 46(3), 275-85

CODEN: IJVNAP

DT Journal

LA English

L18 ANSWER 373 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1977:14902 CAPLUS

DN 86:14902

TI Ascorbic acid metabolism in rats fed high fat cholesterol diet

AU Nambisan, B.; Kurup, P. A.

CS Dep. Biochem., Univ. Kerala, Trivandrum, India

SO Atherosclerosis (1976), 25(1), 63-9

CODEN: ATHSBL

DT Journal

LA English

L18 ANSWER 374 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1976:522214 CAPLUS

DN 85:122214

TI Tissue changes induced by marginal vitamin C deficiency

AU Sulkin, Norman M.; Sulkin, Dorothy F.

CS Bowman Gray Sch. Med., Wake Forest Univ., Winston-Salem, N. C., USA

SO Ann. N. Y. Acad. Sci. (1975), 258(Conf. Vitam. C, 2nd, 1974), 317-28

CODEN: ANYAA9

DT Journal

LA English

L18 ANSWER 375 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:507781 CAPLUS
 DN 85:107781
 TI Induction of **atherosclerosis**. IX. Biochemical studies on
 adrenal and other organs of pigs kept on various experimental diets for 45
 days
 AU Singh, Narendra; Mukherjee, S. K.
 CS Div. Toxicol. Exp. Med., Cent. Drug Res. Inst., Lucknow, India
 SO Indian J. Anim. Res. (1974), 8(2), 47-50
 CODEN: IALRBR
 DT Journal
 LA English

L18 ANSWER 376 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:491523 CAPLUS
 DN 85:91523
 TI The role of ascorbic acid in the regulation of cholesterol metabolism and
 in the pathogenesis of **atherosclerosis**
 AU Turley, S. D.; West, C. E.; Horton, B. J.
 CS John Curtin Sch. Med. Res., Aust. Natl. Univ., Canberra, Aust.
 SO Atherosclerosis (1976), 24(1-2), 1-18
 CODEN: ATHSBL
 DT Journal; General Review
 LA English

L18 ANSWER 377 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:445226 CAPLUS
 DN 85:45226
 TI Vitamin C, blood cholesterol, and **atherosclerosis**
 AU Ginter, Emil
 CS USA
 SO Am. Lab. (1976), 8(6), 21-2, 24-6, 28-9
 CODEN: ALBYBL
 DT Journal; General Review
 LA English

L18 ANSWER 378 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:162685 CAPLUS
 DN 84:162685
 TI Content of vitamin C and B6 in the blood during experimental cholesterol
atherosclerosis
 AU Babadzhanyan, S. N.
 CS Leningr. Inst. Urology, Vrachey, Leningrad, USSR
 SO Med. Zh. Uzb. (1975), (8), 38-41
 CODEN: MZUZA8
 DT Journal
 LA Russian

L18 ANSWER 379 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:42356 CAPLUS
 DN 84:42356
 TI Ascorbic acid and glycosaminoglycan and lipid metabolism in guinea pigs
 fed normal and atherogenic diets
 AU Nambisan, Bala; Kurup, P. A.
 CS Dep. Biochem., Univ. Kerala, Trivandrum, India
 SO Atherosclerosis (1975), 22(3), 447-61
 CODEN: ATHSBL
 DT Journal
 LA English

L18 ANSWER 380 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:562501 CAPLUS

DN 83:162501
 TI Significance of the systemic nature of biological inhibition of lipid peroxidation in atherogenesis
 AU Voskresenskii, O. N.
 CS Odess. Med. Inst. im. Pirogova, Odessa, USSR
 SO Tr. Mosk. O-va. Ispyt. Prir. (1975), 52, 121-5
 CODEN: TMPBAX
 DT Journal
 LA Russian

L18 ANSWER 381 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:562451 CAPLUS
 DN 83:162451
 TI Vitamin C in lipid metabolism and **atherosclerosis**
 AU Ginter, E.
 CS Inst. Hum. Nutr. Res., Bratislava, Czech.
 SO Vitam. C: Recent Aspects Its Physiol. Technol. Importance, Ind.-Univ. Co-op. Symp. (1974), 179-202. Editor(s): Birch, Gordon Gerard; Parker, Kenneth John. Publisher: Wiley, New York, N. Y.
 CODEN: 31JMAT
 DT Conference; General Review
 LA English

L18 ANSWER 382 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:562447 CAPLUS
 DN 83:162447
 TI Role of vitamin C in cholesterol catabolism and atherogenesis
 AU Ginter, Emil
 CS Inst. Hum. Nutr. Res., Bratislava, Czech.
 SO Biol. Pr. (1975), 21(1), 100 pp.
 CODEN: BLGPAT
 DT Journal; General Review
 LA English

L18 ANSWER 383 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:530360 CAPLUS
 DN 83:130360
 TI Experimental **atherosclerosis** due to ascorbic acid deficiency
 AU Fujinami, Takao; Okado, Kota
 CS Med. Sch., Nagoya City Univ., Nagoya, Japan
 SO Atheroscler., Proc. Int. Symp., 3rd (1974), Meeting Date 1973, 326-9. Editor(s): Schettler, Gotthard; Weizel, Achim. Publisher: Springer, New York, N. Y.
 CODEN: 31CGAA
 DT Conference
 LA English

L18 ANSWER 384 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:511958 CAPLUS
 DN 83:111958
 TI Vitamin C and **atherosclerosis**
 AU Lewin, R.
 CS Neth.
 SO Chem. Tech. (Amsterdam) (1975), 30(7), A9-A10
 CODEN: CHTAAW
 DT Journal; General Review
 LA Dutch

L18 ANSWER 385 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1975:490945 CAPLUS
 DN 83:90945
 TI Effect of prophylactic therapy with ascorbic acid, clofibrate, and

reserpine on the development of experimental **atherosclerosis**
AU Zohdy, A.; Kassab, M.; Tawab, S. A.; Akkad, I. N.; El-Din, A. K.; Ammar,
E. M.
CS Fac. Med., Assiut Univ., Assiut, Egypt
SO J. Drug Res. (1974), 6(3), 109-24
CODEN: JDGRAX
DT Journal
LA English

L18 ANSWER 386 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1975:138115 CAPLUS
DN 82:138115
TI Aortic endothelial mitosis and Evans blue uptake in cholesterol-fed
subscorbatic guinea pigs
AU Wright, H. Payling; Evans, M.; Green, R. P.
CS Charles Salt Res. Cent., Robert Jones and Agnes Hunt Orthop. Hosp.,
Oswestry/Salop, Engl.
SO Atherosclerosis (1975), 21(1), 105-13
CODEN: ATHSBL
DT Journal
LA English

L18 ANSWER 387 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1975:2401 CAPLUS
DN 82:2401
TI Vitamin C in lipid metabolism and atherogenesis
AU Ginter, E.; Nemec, R.; Babala, J.
CS Vyzk. Ustav Vyz. Ludu, Bratislava, Czech.
SO Cas. Lek. Cesk. (1974), 113(35), 1049-55
CODEN: CLCEAL
DT Journal
LA Slovak

L18 ANSWER 388 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1974:568042 CAPLUS
DN 81:168042
TI Ascorbate-cholesterol-lecithin interactions. Factors of potential
importance in the pathogenesis of **atherosclerosis**
AU Krumdieck, Carlos; Butterworth, C. E., Jr.
CS Sch. Med., Univ. Alabama, Birmingham, Ala., USA
SO Amer. J. Clin. Nutr. (1974), 27(8), 866-76
CODEN: AJCNAC
DT Journal; General Review
LA English

L18 ANSWER 389 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1974:514486 CAPLUS
DN 81:114486
TI Possible biological and pharmacological significance of L-ascorbic acid
and L-ascorbic acid 2-sulfate on cholesterol metabolism, metabolic
sulfation, and atherogenesis
AU Verlangieri, Anthony
CS Pennsylvania State Univ., University Park, Pa., USA
SO (1973) 110 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No.
74-4299
From: Diss. Abstr. Int. B 1974, 34(8), 3635-7
DT Dissertation
LA English

L18 ANSWER 390 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1973:487597 CAPLUS
DN 79:87597

TI Influence of high doses of L-(+)-ascorbic acid on plasma cholesterol level
in healthy subjects
AU Hanck, A. B.
CS Abt. Vitam. Ernaehrungsforsch., F. Hoffmann-La Roche und Co. A.-G., Basel,
Switz.
SO Z. Ernaehrungswiss. (1973), 12(2), 152-8
CODEN: ZERNAL
DT Journal
LA German

L18 ANSWER 391 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1973:158097 CAPLUS
DN 78:158097

TI Role of ascorbic acid in the metabolism of cholesterol. II. Vitamin C
participation in the biosynthesis of bile acids
AU Ginter, E.
CS Sci.-Res. Inst. Nutr., Bratislava, Czech.
SO Vop. Pitan. (1973), (1), 29-35
CODEN: VPITAR
DT Journal
LA Russian

L18 ANSWER 392 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1973:11679 CAPLUS
DN 78:11679

TI Effect of a complex of water-soluble vitamins on energy processes in
tissues and on the development of experimental **atherosclerosis**
AU Tsiomik, V. A.; Razumnaya, N. M.; Kuz'minskii, N. P.; Garkusha, L. N.;
Kovaleva, N. I.
CS Kiev, USSR
SO Gipertonicheskaya Bolezn, Ateroskler. Koronarnaya Nedostatochnost (1972),
No. 4, 94-9
CODEN: GBAKA3
DT Journal
LA Russian

L18 ANSWER 393 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1972:496995 CAPLUS
DN 77:96995

TI Effect of different doses of biotin on the ascorbic acid allowance in
patients with **atherosclerosis** and hypertensive disease
AU Braginskii, B. M.; Kalkun, D. P.
CS Grodn. Med. Inst., Grodno, USSR
SO Vop. Pitan. (1972), 31(3), 47-50
CODEN: VPITAR
DT Journal
LA Russian

L18 ANSWER 394 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1972:447053 CAPLUS
DN 77:47053

TI Experimental **atherosclerosis** with ascorbic acid deficiency
AU Fujinami, Takao; Okado, Kota; Senda, Katsuji; Sugimura, Muneaki;
Kishikawa, Motoaki
CS Med. Sch., Nagoya City Univ., Nagoya, Japan
SO Jap. Circ. J. (1971), 35(12), 1559-65
CODEN: JCIRA2
DT Journal
LA English

L18 ANSWER 395 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1972:417296 CAPLUS

DN 77:17296
 TI Problems of stabilization of thrombocytes and erythrocytes by flavanoids, ascorbic acid, and tocopherol
 AU Zuern, H.
 CS Bezirksinst. Blutspende-Transfusionswes., Dresden, E. Ger.
 SO Bibl. Haematol. (Basel) (1971), No. 38(Pt. 2), 221-3
 CODEN: BIHAA2
 DT Journal
 LA English

L18 ANSWER 396 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:94611 CAPLUS
 DN 76:94611
 TI Pathomorphological and histochemical changes in rabbit aorta during experimental hypercholesterolemia with the simultaneous administration of methionine
 AU Alkadarskii, S. I.
 CS Dagest. Med. Inst., Makhachkala, USSR
 SO Tr. Volgograd. Gos. Med. Inst. (1970), 23(4), 63-7
 CODEN: TVLMB8
 DT Journal
 LA Russian

L18 ANSWER 397 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:94588 CAPLUS
 DN 76:94588
 TI Biochemical indexes in rabbits with alimentary **atherosclerosis** during the administration of zymosan
 AU Leja, D.; Stuce, M.; Liepa, V.; Bass-Shadkhan, Kh.; Klavina, Z.; Burmeister, M.
 CS Preimate, E., Biokim. Lab., Latv. Eksp. Klin. Med. Zinat. Petniecibas Inst., Riga, USSR
 SO Klin. Eksp. Med. (1971), 4, 193-200
 CODEN: KLEMA7
 DT Journal
 LA Latvian

L18 ANSWER 398 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1971:538228 CAPLUS
 DN 75:138228
 TI Effect of biotin and ascorbic acid on the development of **atherosclerosis** in rabbits
 AU Pool, W. R.; Newmark, H. I.; Dalton, C.; Banziger, R. F.; Howard, A. N.
 CS Res. Div., Hoffmann-La Roche, Inc., Nutley, N. J., USA
 SO Atherosclerosis (1971), 14(1), 131-5
 CODEN: ATHSBL
 DT Journal
 LA English

L18 ANSWER 399 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1971:433757 CAPLUS
 DN 75:33757
 TI Influence of vitamin C on cholesterol metabolism in the liver in experimental **atherosclerosis**
 AU Novitskii, A. A.
 CS Dep. Mil. Nav. Hosp. Ther., Kirov Mil. Med. Acad., Kuibyshev, USSR
 SO Cor Vasa (1969), 11(4), 302-10
 CODEN: COVAAN
 DT Journal
 LA English

L18 ANSWER 400 OF 420 CAPLUS COPYRIGHT 2002 ACS

AN 1971:139228 CAPLUS
DN 74:139228
TI Effect of ascorbic acid on the biosynthesis of cholesterol in the early stages of experimental **atherosclerosis**
AU Novitskii, A. A.
CS Voenno-Med. Akad. im. Kirova, Leningrad, USSR
SO Kardiologiya (1970), 10(12), 118-19
CODEN: KARDA2
DT Journal
LA Russian

L18 ANSWER 401 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1971:96182 CAPLUS
DN 74:96182
TI Metabolism of L-ascorbic acid-1-14C in guinea pigs with alimentary cholesterol atheromatosis
AU Ginter, Emil; Zloch, Zdenek; Cerven, J.; Nemec, Rudolf; Babala, Jozef
CS Inst. Hum. Nutr. Res., Brastislava, Czech.
SO J. Nutr. (1971), 101(2), 197-204
CODEN: JONUAI
DT Journal
LA English

L18 ANSWER 402 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1970:495965 CAPLUS
DN 73:95965
TI Biochemical bases of **atherosclerosis** prophylaxis
AU Shamrai, E. F.
CS USSR
SO Vrach. Delo (1970), (4), 42-6
CODEN: VRDEA5
DT Journal
LA Russian

L18 ANSWER 403 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1970:485640 CAPLUS
DN 73:85640
TI Ascorbic acid requirements in atherosclerotic and hypertonic diseases
AU Braginskii, B. M.; Kalkun, D. P.
CS Grodn. Med. Inst., Grodno, USSR
SO Vop. Pitan. (1970), 29(4), 25-8
CODEN: VPITAR
DT Journal
LA Russian

L18 ANSWER 404 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1970:464234 CAPLUS
DN 73:64234
TI Ascorbic acid level in blood and tissues during experimental **atherosclerosis** under the influence of sodium chloride baths
AU Dolina, L. A.; Kubli, S. Kh.
CS Patomorfol. Lab., Tsent. Inst. Kurortol. Fizioter., Moscow, USSR
SO Vop. Kurortol., Fizioter. Lech. Fiz. Kul't. (1970), 35(1), 31-4
CODEN: VKFLAL
DT Journal
LA Russian

L18 ANSWER 405 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1970:464233 CAPLUS
DN 73:64233
TI Change in the ascorbic acid level of tissues during experimental **atherosclerosis** and under the influence of hydrogen sulfide baths

AU Shalimov, V. A.
 CS Biokhim. Lab., Tsent. Inst. Kurortol. Fizioter., Moscow, USSR
 SO Vop. Kurortol., Fizioter. Lech. Fiz. Kul't. (1970), 35(1), 28-30
 CODEN: VKFLAL
 DT Journal
 LA Russian

L18 ANSWER 406 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:443119 CAPLUS
 DN 73:43119
 TI Correlations of the metabolism of cholesterol and ascorbic acid during prolonged experimental hypercholesterolemia
 AU Novitskii, A. A.
 CS Kuibyshev. Med. Inst., Kuibyshev, USSR
 SO Tr. Kuibyshev. Med. Inst. (1969), 56, 122-7
 CODEN: TKUMA9
 DT Journal
 LA Russian

L18 ANSWER 407 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:423336 CAPLUS
 DN 73:23336
 TI Sulfhydryl compounds and **atherosclerosis**
 AU Takagi, Yukio
 CS Sch. Med., Nagoya Univ., Nagoya, Japan
 SO Nagoya J. Med. Sci. (1970), 32(2), 281-302
 CODEN: NJMSAG
 DT Journal
 LA English

L18 ANSWER 408 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:412403 CAPLUS
 DN 73:12403
 TI Antioxidants in **atherosclerosis**
 AU Iwahashi, Hiroshi
 CS Sch. Med., Nagoya Univ., Nagoya, Japan
 SO Nagoya J. Med. Sci. (1970), 32(2), 327-45
 CODEN: NJMSAG
 DT Journal
 LA English

L18 ANSWER 409 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1970:76779 CAPLUS
 DN 72:76779
 TI Morphological signs of the functional condition of the adrenal cortex in experimental **atherosclerosis**
 AU Lushnikova, L. A.; Fedorova, M. K.
 CS Kazan. Inst. Usoversh. Vrach. im. Lenina, Kazan, USSR
 SO Arkh. Patol. (1969), 31(11), 36-40
 CODEN: ARPTAF
 DT Journal
 LA Russian

L18 ANSWER 410 OF 420 CAPLUS COPYRIGHT 2002 ACS
 AN 1969:511257 CAPLUS
 DN 71:111257
 TI Effect of ascorbic acid on the development of experimental **atherosclerosis**
 AU Rzakulieva, D. M.
 CS USSR
 SO Izv. Akad. Nauk Azerb. SSR, Ser. Biol. Nauk (1969), (2), 110-13
 CODEN: IABLAQ

DT Journal
LA Russian

L18 ANSWER 411 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1969:458348 CAPLUS
DN 71:58348
TI Changes of the intensity of cholesterol biosynthesis under the effect of ascorbic acid at early stages of experimental **atherosclerosis**
AU Novitskii, A. A.; Ivanov, A. I.; Reshetnev, V. G.
CS Voenno-Med. Akad. im. Kirova, Leningrad, USSR
SO Patol. Fiziol. Eksp. Ter. (1969), 13(3), 59-62
CODEN: PAFEAY
DT Journal
LA Russian

L18 ANSWER 412 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1969:112787 CAPLUS
DN 70:112787
TI Effect of vitamin C on cholesterol metabolism and atherogenesis
AU Ginter, Emil
CS Vysk. Ustav. Vyzivy Ludu, Bratislava, Czech.
SO Cesk. Fysiol. (1968), 17(5), 423-36
CODEN: CEFYAD
DT Journal; General Review
LA Czech

L18 ANSWER 413 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1969:75928 CAPLUS
DN 70:75928
TI Ascorbic acid metabolism at an early stage of experimental **atherosclerosis**
AU Novitskii, A. A.
CS Voenno-Med. Akad. im. Kirova, Leningrad, USSR
SO Kardiologiya (1968), 8(8), 33-6
CODEN: KARDA2
DT Journal
LA Russian

L18 ANSWER 414 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1969:9650 CAPLUS
DN 70:9650
TI Lingual vitamin C test. VII. Relation of nonfasting serum cholesterol and vitamin C state
AU Cheraskin, E.; Ringsdorf, W. M., Jr.
CS Med. Center, Univ. of Alabama, Birmingham, Ala., USA
SO Int. Z. Vitaminforsch. (1968), 38(3-4), 415-20
CODEN: IZVIAK
DT Journal
LA English

L18 ANSWER 415 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1968:494978 CAPLUS
DN 69:94978
TI Inhibitory effect of papaverine hydrochloride and ascorbic acid on the development of experimental **atherosclerosis**
AU Bedzhanyan, Zh. S.; Martikyan, M. S.
CS Erevan. Klin. Bol. "Malat'ya", Erevan, USSR
SO Zh. Eksp. Klin. Med. (1968), 8(1), 35-42
CODEN: ZKMAAX
DT Journal
LA Russian

L18 ANSWER 416 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1968:37230 CAPLUS
DN 68:37230
TI Long-term nutrition survey of population in an area with low incidence of
atherosclerosis
AU Osancova, Katerina; Hejda, Stanislav
CS Ustav Vyzkum Vyzivy Lidu, Prague, Czech.
SO Cesk. Gastroenterol. Vyz. (1967), 21(7), 482-7
CODEN: CKGAAM
DT Journal
LA Czech

L18 ANSWER 417 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1967:114523 CAPLUS
DN 66:114523
TI Ascorbic acid and fibrinolysis in **atherosclerosis**
AU Shershevskii, M. G.
CS Novokuznetsk Inst. Postgrad. Med., Novokuznetsk, USSR
SO Kardiologiya (1965), 5(4), 64-5
From: Biol. Abstr. 1966, 47(11), 4403
CODEN: KARDA2
DT Journal
LA Russian

L18 ANSWER 418 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1967:93224 CAPLUS
DN 66:93224
TI Histochemical study of the kidneys under conditions of
hypercholesterolemia
AU Lutsenko, M. T.
SO Tr. Blagoveshch. Gos. Med. Inst. (1966), 8, 155-6
From: Ref. Zh., Biol. Khim. 1966, Abstr. No. 22F1305
CODEN: TBMIAU
DT Journal
LA Russian

L18 ANSWER 419 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1967:53335 CAPLUS
DN 66:53335
TI Effect of vitamins B6, B12, and C on amino acid balance in blood during
coronary **atherosclerosis**, myocardial infarction, and hypertonia
AU Sulimovskaya, N. A.; Brovko-Burkhanova, N. Z.; Konakov, N. M.;
Kamenetskaya, V. Ya.
SO Kazan. Med. Zh. (1966), (5), 10-13
CODEN: KAMZA9
DT Journal
LA Russian

L18 ANSWER 420 OF 420 CAPLUS COPYRIGHT 2002 ACS
AN 1967:1387 CAPLUS
DN 66:1387
TI Effects of L-triiodothyronine, nicotinic acid, and ascorbic acid on the
electrophoretic pattern of serum lipoproteins in cockerels
AU Tantengco, Victor O.; Somera, Lina C.; Credo, Elenita
SO Acta Med. Philipp. (1966), 3(1), 13-19
CODEN: AMPIAF
DT Journal
LA English

=> s 16

L19 26899 L6

=> s 119 and 110
L20 800 L19 AND L10

=> d 120 750-800

- L20 ANSWER 750 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1987:476626 CAPLUS
DN 107:76626
TI The effect of vitamin E on the development of pulmonary emphysema in experimental arteriosclerosis
AU Radak, D.; Djordjevic-Denic, Gordana; Cvetkovic, P.; Perovic, Marija; Vukovic, J.
CS Inst. Pathol. Physiol., Fac. Med., Belgrade, Yugoslavia
SO Jugoslavica Physiologica et Pharmacologica Acta (1986), 22(3), 281-6
CODEN: IPPABX; ISSN: 0021-3225
DT Journal
LA English
- L20 ANSWER 751 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1987:475431 CAPLUS
DN 107:75431
TI The role of prostacyclin and thromboxane A2 in the formation of experimental arteriosclerosis in rabbits
AU Zhou, Jianpign; Zhou, Weisen; Wang, Yuping; Ji, Hong; Hou, Xin
CS Dep. Physiol., Tianjin 2nd Med. Coll., Tianjin, Peop. Rep. China
SO Tianjin Yiyao (1986), 14(12), 718-20
CODEN: TIYADG; ISSN: 0253-9896
DT Journal
LA Chinese
- L20 ANSWER 752 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1987:31702 CAPLUS
DN 106:31702
TI Vitamin C increases the prostacyclin production and decreases the vascular lesions in experimental **atherosclerosis** in rabbits
AU Beetens, J. R.; Coene, M. C.; Verheyen, A.; Zonnekeyn, L.; Herman, A. G.
CS Fac. Med., Univ. Antwerp, Wilrijk, B2610, Belg.
SO Prostaglandins (1986), 32(3), 335-52
CODEN: PRGLBA; ISSN: 0090-6980
DT Journal
LA English
- L20 ANSWER 753 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1986:422458 CAPLUS
DN 105:22458
TI Lipid peroxidation and **atherosclerosis**
AU Liu, Shizhong; Lin, Zhuangji; Huang, Gusong; Chen, Yiling; Chen, Zhiqiong; Zhang, Hongyan
CS Dep. Biochem., Guangdong Coll. Pharm., Guangdong, Peop. Rep. China
SO Zhonghua Yixue Zazhi (Beijing, China) (1985), 65(9), 554-5
CODEN: CHHTAT; ISSN: 0300-2578
DT Journal
LA Chinese
- L20 ANSWER 754 OF 800 CAPLUS COPYRIGHT 2002 ACS
AN 1986:147555 CAPLUS
DN 104:147555
TI Effects of vitamin C and E, trace element selenium and brown sugar in guinea pig arteriosclerosis
AU Sun, Yuming; Lu, Tianluan; Gao, Jianzhong; Dou, Shulan; Wang, Hong; Sun, Shuqin; Li, Tianyang; Sun, Rui

Response to medical and surgical therapy

AU Ritchie, James L.; Harker, Laurence A.
 CS Sch. Med., Univ. Washington, Seattle, WA, USA
 SO American Journal of Cardiology (1977), 39(4), 595-8
 CODEN: AJCDAG; ISSN: 0002-9149
 DT Journal
 LA English

L7 ANSWER 198 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1975:93102 CAPLUS
 DN 82:93102
 TI Suppression of atheromatous fibrous plaque formation by antiproliferative
 and antiinflammatory drugs
 AU Hollander, William; Kramsch, Dieter M.; Franzblau, Carl; Paddock, John;
 Colombo, Marilyn A.
 CS Med. Cent., Boston Univ., Boston, MA, USA
 SO Circulation Research, Supplement (1974), 34(5, Suppl. 1), 131-41
 CODEN: CIRSAF; ISSN: 0069-4185
 DT Journal
 LA English

L7 ANSWER 199 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1974:534149 CAPLUS
 DN 81:134149
 TI Arterial and venous thromboembolism. Kinetic characterization and
 evaluation of therapy
 AU Harker, Laurence A.; Slichter, Sherrill J.
 CS Sch. Med., Univ. Washington, Seattle, WA, USA
 SO Thrombosis et Diathesis Haemorrhagica (1974), 31(2), 188-203
 CODEN: TDHAAT; ISSN: 0340-5338
 DT Journal
 LA English

L7 ANSWER 200 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1973:500515 CAPLUS
 DN 79:100515
 TI Antiinflammatory drugs in experimental **atherosclerosis**. 1.
 Relative potencies for inhibiting plaque formation
 AU Bailey, J. Martyn; Butler, Jean
 CS Sch. Med., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1973), 17(3), 515-22
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English

L7 ANSWER 201 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:9364 CAPLUS
 DN 66:9364
 TI Influence of antiinflammatory agents on experimental
atherosclerosis
 AU Bailey, John Martyn; Butler, Jean
 CS Sch. of Med., George Washington Univ., Washington, DC, USA
 SO Nature (London, United Kingdom) (1966), 212(5063), 731-2
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English

L7 ANSWER 202 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1966:78912 CAPLUS
 DN 64:78912
 OREF 64:14834c-d
 TI Antisclerotic drug containing corn oil

AU Pivnenko, G. P.; Sotnikova, O. M.; Kharchenko, M. S.; Kutsevich, V. A.;
Mala, L. T.; Safronova, V. I.
SO Farmatsevt. Zh. (Kiev) (1965), 20(6), 10-12
DT Journal
LA Ukrainian

=> s l3 or l4

L10 39179 L3 OR L4

=> s l10 and l6

L11 143 L10 AND L6

=> d l11 100-143

L11 ANSWER 100 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:444877 CAPLUS
DN 133:68626
TI The effect of cholesterol lowering on carotid and femoral artery wall
stiffness and thickness in patients with familial hypercholesterolemia
AU Smilde, T. J.; Van den Berkmortel, F. W.; Wollersheim, H.; Van Langen, H.;
Kastelein, J. J.; Stalenhoef, A. F. H.
CS University Hospital Nijmegen, Nijmegen, 6500 HB, Neth.
SO European Journal of Clinical Investigation (2000), 30(6), 473-480
CODEN: EJCIB8; ISSN: 0014-2972
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 101 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:431856 CAPLUS
DN 133:53486
TI Additional efficacy of milligram-equivalent doses of atorvastatin over
simvastatin
AU Van Dam, Marjel; Basart, Dick C. G.; Janus, Charles; Zwertbroek, Rolf;
Spierenburg, Han A. M.; Werner, Hans A.; Bredero, A. C.; Lansberg, Peter
J.; Jonker, Carla J.; Trip, Mieke D.; Prins, Martin H.; Kastelein, John J.
P.
CS Department of Vascular Medicine, Academic Medical Center, Amsterdam, Neth.
SO Clinical Drug Investigation (2000), 19(5), 327-334
CODEN: CDINFR; ISSN: 1173-2563
PB Adis International Ltd.
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 102 OF 143 CAPLUS COPYRIGHT 2003 ACS
AN 2000:190929 CAPLUS
DN 132:231970
TI Method for treating **atherosclerosis** employing an ap2 inhibitor,
and pharmaceutical combinations with other agents
IN Robl, Jeffrey A.; Parker, Rex A.; Biller, Scott A.; Jamil, Haris;
Jacobson, Bruce L.; Kodukula, Krishna
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000015230	A1	20000323	WO 1999-US21069	19990913
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2344300	AA	20000323	CA 1999-2344300	19990913
	AU 9961437	A1	20000403	AU 1999-61437	19990913
	BR 9913831	A	20010529	BR 1999-13831	19990913
	EP 1113801	A1	20010711	EP 1999-948210	19990913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2001001352	A	20010511	NO 2001-1352	20010316
	LT 4871	B	20011227	LT 2001-22	20010316
	LT 4870	B	20011227	LT 2001-23	20010316
	LV 12687	B	20011020	LV 2001-58	20010412
	US 2002035064	A1	20020321	US 2001-905235	20010713
PRAI	US 1998-100677P	P	19980917		
	US 1999-390275	B1	19990907		
	WO 1999-US21069	W	19990913		
OS	MARPAT 132:231970				
RE.CNT	2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L11 ANSWER 103 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:189750 CAPLUS
 DN 132:343112
 TI Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin
 AU Johnston, T. P.; Baker, J. C.; Hall, D.; Jamal, S.; Palmer, W. K.; Emeson, E. E.
 CS School of Pharmacy, Division of Pharmaceutical Sciences, University of Missouri, Kansas City, MO, USA
 SO Atherosclerosis (Shannon, Ireland) (2000), 149(2), 303-313
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 104 OF 143 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:172806 CAPLUS
 DN 132:329688
 TI Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease
 AU Kato, T.; Tokoro, T.; Namii, Y.; Kobayashi, T.; Hayashi, S.; Yokoyama, I.; Morimoto, S.; Chan, M.; Giannetti, N.; Hunt, S. A.
 CS Department of Surgery II, Nagoya University School of Medicine, Nagoya, Japan
 SO Transplantation Proceedings (2000), 32(2), 331-333
 CODEN: TRPPA8; ISSN: 0041-1345
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS EXPRESS			January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information

NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:19:37 ON 23 JAN 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 23 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2003 HIGHEST RN 480390-21-4

DICTIONARY FILE UPDATES: 22 JAN 2003 HIGHEST RN 480390-21-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e asprin

E1	8	ASPRELLA/BI
E2	3	ASPRELLIC/BI
E3	0 -->	ASPRIN/BI
E4	1	ASPRIODINE/BI
E5	3	ASPRO/BI
E6	2	ASPROCOTTUS/BI
E7	1	ASPROK/BI
E8	1	ASPROKOL/BI
E9	1	ASPROPHARM/BI
E10	2	ASPROTILAPIA/BI
E11	5	ASPRS/BI
E12	1	ASPRSE/BI

```
=> e aspirin
E1      1      ASPIRALIS/BI
E2      1      ASPIRDROPS/BI
E3      50 --> ASPIRIN/BI
E4      2      ASPIRINA/BI
E5      1      ASPIRISINE/BI
E6      11     ASPIRO/BI
E7      1      ASPIROCH/BI
E8      2      ASPIROCHLORINE/BI
E9      1      ASPIROCHOLINE/BI
E10     1      ASPIROCHYL/BI
E11     4      ASPIRYL/BI
E12     1      ASPIRYLAMINO/BI
```

```
=> s e3
L1      50 ASPIRIN/BI
```

```
=> e atorvastatin
E1      8      ATORV/BI
E2      8      ATORVASTAT/BI
E3      8 --> ATORVASTATIN/BI
E4      10580   ATORY/BI
E5      134     ATORYN/BI
E6      134     ATORYNCHUS/BI
E7      81     ATOS/BI
E8      1      ATOS70F/BI
E9      1      ATOSA/BI
E10     2      ATOSAL/BI
E11     1      ATOSALM/BI
E12     5      ATOSAMAR/BI
```

```
=> s e2-e3
      8 ATORVASTAT/BI
      8 ATORVASTATIN/BI
L2      8 (ATORVASTAT/BI OR ATORVASTATIN/BI)
```

```
=> file caplus
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                   ENTRY      SESSION
FULL ESTIMATED COST                14.66      14.87
```

FILE 'CAPLUS' ENTERED AT 10:22:28 ON 23 JAN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jan 2003 VOL 138 ISS 4
 FILE LAST UPDATED: 22 Jan 2003 (20030122/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

15.29

FILE 'REGISTRY' ENTERED AT 10:22:39 ON 23 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JAN 2003 HIGHEST RN 480390-21-4

DICTIONARY FILE UPDATES: 22 JAN 2003 HIGHEST RN 480390-21-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STN Note 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d his

(FILE 'HOME' ENTERED AT 10:19:37 ON 23 JAN 2003)

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 23 JAN 2003

E ASPRIN

E ASPIRIN

L1 50 S E3

E ATORVASTATIN

L2 8 S E2-E3

FILE 'CAPLUS' ENTERED AT 10:22:28 ON 23 JAN 2003

FILE 'REGISTRY' ENTERED AT 10:22:39 ON 23 JAN 2003

=> d 12 8

L2 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2003 ACS

RN 125995-03-1 REGISTRY

CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-
diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-
diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-,
(2R-trans)-

OTHER NAMES:

CN **Atorvastatin .delta.-lactone**

CN **Atorvastatin lactone**


FS STEREOSEARCH

DR 142062-65-5

MF C33 H33 F N2 O4

SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, MRCK*, TOXCENTER, USPAT2,
USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

28 REFERENCES IN FILE CA (1962 TO DATE)
28 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.08	17.37

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:23:00 ON 23 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jan 2003 VOL 138 ISS 4
FILE LAST UPDATED: 22 Jan 2003 (20030122/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e atherosclerosis

E1	1	ATHEROSCLEROSIA/BI
E2	4	ATHEROSCLEROSIC/BI
E3	33649 -->	ATHEROSCLEROSIS/BI
E4	1	ATHEROSCLEROSIS8/BI
E5	1	ATHEROSCLEROSISARE/BI
E6	1	ATHEROSCLEROSISATHEROSCLEROSIS/BI
E7	1	ATHEROSCLEROSISHATHEROSCLEROSIS/BI
E8	1	ATHEROSCLEROSOIS/BI
E9	2	ATHEROSCLEROSOS/BI
E10	1	ATHEROSCLEROSS/BI
E11	1	ATHEROSCLEROSTIC/BI
E12	1	ATHEROSCLEROT/BI

=> s e3

L3 33649 ATHEROSCLEROSIS/BI

=> e arteriosclerosis

E1	3	ARTERIOSCLEROSES/BI
E2	1	ARTERIOSCLEROSI/BI
E3	9434 -->	ARTERIOSCLEROSIS/BI
E4	1	ARTERIOSCLEROSISIN/BI
E5	1	ARTERIOSCLEROSISINDUCING/BI
E6	1	ARTERIOSCLEROSOGENESIS/BI
E7	1231	ARTERIOSCLEROTIC/BI
E8	1	ARTERIOSCLEROTICA/BI
E9	2	ARTERIOSCLEROTICALLY/BI
E10	52	ARTERIOSCLEROTICS/BI
E11	2	ARTERIOSCLEROTIES/BI
E12	1	ARTERIOSCLERROSIS/BI

=> s e1-e12

	3	ARTERIOSCLEROSES/BI
	1	ARTERIOSCLEROSI/BI
	9434	ARTERIOSCLEROSIS/BI
	1	ARTERIOSCLEROSISIN/BI
	1	ARTERIOSCLEROSISINDUCING/BI
	1	ARTERIOSCLEROSOGENESIS/BI
	1231	ARTERIOSCLEROTIC/BI
	1	ARTERIOSCLEROTICA/BI
	2	ARTERIOSCLEROTICALLY/BI
	52	ARTERIOSCLEROTICS/BI
	2	ARTERIOSCLEROTIES/BI
	1	ARTERIOSCLERROSIS/BI
L4	9906	(ARTERIOSCLEROSES/BI OR ARTERIOSCLEROSI/BI OR ARTERIOSCLEROSIS/B I OR ARTERIOSCLEROSISIN/BI OR ARTERIOSCLEROSISINDUCING/BI OR ARTERIOSCLEROSOGENESIS/BI OR ARTERIOSCLEROTIC/BI OR ARTERIOSCLER OTICA/BI OR ARTERIOSCLEROTICALLY/BI OR ARTERIOSCLEROTICS/BI OR ARTERIOSCLEROTIES/BI OR ARTERIOSCLERROSIS/BI)

=> d his

(FILE 'HOME' ENTERED AT 10:19:37 ON 23 JAN 2003)

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 23 JAN 2003

E ASPRIN

E ASPIRIN

L1 50 S E3

E ATORVASTATIN

L2 8 S E2-E3

FILE 'CAPLUS' ENTERED AT 10:22:28 ON 23 JAN 2003

FILE 'REGISTRY' ENTERED AT 10:22:39 ON 23 JAN 2003

FILE 'CAPLUS' ENTERED AT 10:23:00 ON 23 JAN 2003

E ATHEROSCLEROSIS

L3 33649 S E3

E ARTERIOSCLEROSIS

L4 9906 S E1-E12

=> s l1

L5 16388 L1

=> s l2

L6 725 L2

=> s l5 and l3

L7 202 L5 AND L3

=> s l5 and l4

L8 46 L5 AND L4

=> s l8 not l7

L9 29 L8 NOT L7

=> s l9 5-29

MISSING OPERATOR L9 5-29

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l9 5-29

L9 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 2001:886157 CAPLUS

DN 136:11105

TI Cobalamin compounds useful as cardiovascular agents and as imaging agents

IN Collins, Douglas A.; Hogenkamp, Henricus P. C.

PA Mayo Foundation for Medical Education and Research, USA; Regents of the University of Minnesota

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001092283	A2	20011206	WO 2001-US17694	20010531
	WO 2001092283	A3	20020704		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002049155	A1	20020425	US 2001-873142	20010531
PRAI	US 2000-208140P	P	20000531		
	US 2001-267782P	P	20010209		
OS	MARPAT 136:11105				

L9 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 2001:614876 CAPLUS
 DN 135:147435
 TI Pharmaceutical compositions containing tetrahydroisoquinoline compounds,
 and use for the treatment of heart failure and other conditions
 IN Yun-Choi, Hye Sook; Chang, Ki-Churl; Lee, Duck-Hyung; Ryu, Jae-Chun
 PA Korea Institute of Science and Technology, S. Korea
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023078	A1	20000427	WO 1999-KR631	19991021
	W: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	RW: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	KR 2000028711	A	20000525	KR 1999-41208	19990922
	AU 9963702	A1	20000508	AU 1999-63702	19991021
	EP 1124554	A1	20010822	EP 1999-951228	19991021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002527479	T2	20020827	JP 2000-576852	19991021
PRAI	KR 1998-44128	A	19981021		
	KR 1999-41208	A	19990922		
	WO 1999-KR631	W	19991021		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:50487 CAPLUS
 DN 134:105882
 TI Combination of chromium and vanadium for glucose metabolism disorders
 IN Fine, Stuart A.
 PA Akesis Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001003700	A1	20010118	WO 1999-US15585	19990708
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9950944	A1	20010130	AU 1999-50944	19990708
PRAI	WO 1999-US15585	A	19990708		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:867237 CAPLUS
 DN 135:86783
 TI Assessment of antithrombotic agents using the platelet aggregation test
 AU Tanemoto, Kazuo; Kanaoka, Yuji; Kuinose, Masahiko
 CS Department of Cardiovascular Surgery, Iwakuni National Hospital,
 Yamaguchi, Japan
 SO Current Therapeutic Research (2000), 61(11), 798-806
 CODEN: CTCEA9; ISSN: 0011-393X
 PB Excerpta Medica, Inc.
 DT Journal
 LA English
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:861482 CAPLUS
 DN 134:32977
 TI Methods and compositions for the treatment of neuroleptic and related
 disorders using sertindole derivatives
 IN Jerussi, Thomas P.
 PA Sepracor Inc., USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2000072837	A2	20001207	WO 2000-US14984	20000531
	WO 2000072837	A3	20010517		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6489341	B1	20021203	US 2000-580492	20000530
PRAI	US 1999-137447P	P	19990602		
	US 2000-580492	A	20000530		

L9 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:383951 CAPLUS
 DN 133:22445
 TI Pharmaceutical composition containing fish oil, vitamins E and C, and
 acetylsalicylic acid against **arteriosclerosis**
 IN Langhoff, Wolfgang; Laumann, Udo
 PA Germany
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2000032210	A1	20000608	WO 1999-EP6408	19990901
	W:	CA, CN, US			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,			

PT, SE
 DE 19855426 A1 20000608 DE 1998-19855426 19981202
 EP 1135146 A1 20010926 EP 1999-942931 19990901
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRAI DE 1998-19855426 A 19981202
 WO 1999-EP6408 W 19990901
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:116884 CAPLUS
 DN 132:146639
 TI Combination of active substances, especially for the prophylaxis and
 therapy of ischemic organic lesions and reperfusion syndromes
 IN Nees, Stephan
 PA Vascular Biotech G.m.b.H., Germany
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007578	A2	20000217	WO 1999-DE2478	19990806
	WO 2000007578	A3	20000511		
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9964628	A1	20000228	AU 1999-64628	19990806
	EP 1100539	A2	20010523	EP 1999-952335	19990806
	EP 1100539	B1	20021120		
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
	AT 228011	E	20021215	AT 1999-952335	19990806
PRAI	DE 1998-19835674	A	19980806		
	DE 1998-19844116	A	19980925		
	WO 1999-DE2478	W	19990806		

L9 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:780258 CAPLUS
 DN 132:50
 TI Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia
 AU Michiels, Jan Jacques
 CS Thrombocythemia Vera Study Group, European Working Group on Myeloproliferative Disorders. Goodheart Institute Rotterdam, and Department of Clinical Hematology, Academic Medical Center, MPD Center Europe, Amsterdam, Neth.
 SO Clinical and Applied Thrombosis/Hemostasis (1999), 5(4), 247-251
 CODEN: CATHF9; ISSN: 1076-0296
 PB Lippincott Williams & Wilkins
 DT Journal; General Review
 LA English
 RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:646188 CAPLUS
 DN 131:252346
 TI A case with renovascular hypertension
 AU Kisters, K.; Reimers, P.; Koch, M.; Lorenz, G.; Barenbrock, M.; Vestring, T.; Rahn, K. H.
 CS Medical Policlinic, Univ. Munster, Munster, D-48149, Germany
 SO Clinical Nephrology (1999), 52(4), 263-264
 CODEN: CLNHBI; ISSN: 0301-0430
 PB Dustri-Verlag Dr. Karl Feistle
 DT Journal
 LA English
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:247642 CAPLUS
 DN 118:247642
 TI Method of selecting optimum dose of acetylsalicylic acid in arterial thrombosis
 IN Tegelekov, Bajrammukhamed K.; Kurdov, Kovsy K.; Khudajbergenov, Murad A.
 PA Turkmenskij g med institut, USSR
 SO U.S.S.R.
 From: Izobreteniya 1992, (37), 164.
 CODEN: URXXAF
 DT Patent
 LA Russian
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1767429	A1	19921007	SU 1989-4656212	19890228
PRAI	SU 1989-4656212		19890228		

L9 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:175822 CAPLUS
 DN 118:175822
 TI Cure for diabetes, bronchitis, arthritis, and **arteriosclerosis**
 IN Carantinos, Spyros
 PA Australia
 SO Pat. Specif. (Aust.), 11 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

L9 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:178389 CAPLUS
 DN 114:178389
 TI Anticholesteremic drug combinations comprising a squalene synthetase inhibitor and a second drug
 IN Biller, Scott Adams; Karanewsky, Donald Steven; Gordon, Eric Michael; Scott, William Addison
 PA Squibb, E. R., and Sons, Inc., USA
 SO Ger. Offen., 9 pp.
 CODEN: GWXXBX
 DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 4002825	A1	19900802	DE 1990-4002825	19900131
	DE 4002825	C2	19980827		
	CA 2007641	AA	19900801	CA 1990-2007641	19900112
	GB 2227663	A1	19900808	GB 1990-2018	19900130
	GB 2227663	B2	19930317		
	FR 2642310	A1	19900803	FR 1990-1123	19900131
	FR 2642310	B1	19911025		
	JP 02235820	A2	19900918	JP 1990-23627	19900201
PRAI	US 1989-304534		19890201		
OS	MARPAT 114:178389				

L9 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 1990:637843 CAPLUS

DN 113:237843

TI Pharmaceutical composition containing ferric ammonium citrate and zinc oxide

IN Carantinos, Spyros

PA Australia

SO Eur. Pat. Appl., 5 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 372676	A1	19900613	EP 1989-305729	19890607
	R: CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
PRAI	AU 1988-1849		19881208		

L9 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 1990:210471 CAPLUS

DN 112:210471

TI Necessity and method for the individual dosing of acetyl salicyclic acid for the antithrombotic treatment of arterial circulatory disturbance

AU Norden, Cornelia; Heine, Horst; Schuchardt, Christa; Misselwitz, Frank

CS Zentralinst. Herz-Kreislauf-Forsch, Akad. Wiss. DDR, Berlin, DDR-1115, Ger. Dem. Rep.

SO Zeitschrift fuer Klinische Medizin (1985) (1990), 45(5), 447-51

CODEN: ZKMEEF; ISSN: 0233-1608

DT Journal

LA German

L9 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 1988:431387 CAPLUS

DN 109:31387

TI Significance of acetylsalicylic acid in the secondary prevention of peripheral arterial occlusion

AU Eckstein, H. H.; Mueller-Buehl, U.; Zimmermann, R.; Diehm, C.

CS Abt. Inn. Med. III, Med. Universitaetsklin., Heidelberg, 6900/1, Fed. Rep. Ger.

SO DMW, Dtsch. Med. Wochenschr. (1988), 113(20), 822-7

CODEN: DDMWDF

DT Journal; General Review

LA German

L9 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS

AN 1988:416820 CAPLUS

DN 109:16820

TI Antiplatelets effects of sodium ferulate and aspirin
 AU Zhang, Jin; Meng, Jiamei; Ding, Mingcheng; Pang, Shiqi; Xi, Shuqin; Geng, Yonghui; Wen, Mei; Song, Shizhen; Han, Dianliang
 CS Capital Med. Coll., Xuanwu Hosp., Beijing, Peop. Rep. China
 SO Beijing Yixue (1987), 9(5), 272-3
 CODEN: PCIHD7; ISSN: 0253-9713
 DT Journal
 LA Chinese

L9 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:564744 CAPLUS
 DN 105:164744
 TI Effect of acetylsalicylic acid on pulmonary **arteriosclerosis** induced by a one-year *Dirofilaria immitis* infection
 AU Rawlings, Clarence A.; Keith, James C., Jr.; Schaub, Robert G.
 CS Coll. Vet. Med., Univ. Georgia, Athens, GA, 30602, USA
 SO Arteriosclerosis (Dallas) (1985), 5(4), 355-65
 CODEN: ARTRDW; ISSN: 0276-5047
 DT Journal
 LA English

L9 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:193197 CAPLUS
 DN 104:193197
 TI Dilazep formaulations for treatment of arterioscelrosis
 IN Nagakura, Masahiko; Takimoto, Masami
 PA Kohjin Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 60258118	A2	19851220	JP 1984-116248	19840606
	JP 04003362	B4	19920123		
	EP 170361	A1	19860205	EP 1985-303747	19850529
	EP 170361	B1	19890802		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
PRAI	JP 1984-116248		19840606		

L9 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:179995 CAPLUS
 DN 104:179995
 TI Study of the platelet aggregation test. V. Effect of antiplatelet agents on platelet aggregation in **arteriosclerotic** disease
 AU Tanaka, Yasuo; Migita, Toshimasa; Matsuo, Ryuichi; Ishida, Nobuhiko; Fujimoto, Takashi; Baba, Yoshiyuki; Inoue, Tomio; Satoh, Hideaki; Satoh, Yoshihiko; Tohno, Toshio
 CS Sch. Med., Kyorin Univ., Tokyo, 181, Japan
 SO Kyorin Igakkai Zasshi (1985), 16(4), 513-19
 CODEN: KIZSB8; ISSN: 0368-5829
 DT Journal
 LA Japanese

L9 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1985:605968 CAPLUS
 DN 103:205968
 TI The influence of antiplatelet drugs on injury-stimulated migration of cultured smooth muscle cells
 AU Grunwald, J.; Haudenschild, C. C.
 CS Sch. Med., Boston Univ., Boston, MA, 02161, USA

SO Artery (Fulton, MI, United States) (1985), 12(5), 324-36
 CODEN: ARTEDR; ISSN: 0098-6127

DT Journal
 LA English

L9 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1980:90037 CAPLUS
 DN 92:90037

TI Noninvasive radioisotopic technique for detection of platelet deposition
 in coronary artery bypass grafts in dogs and its reduction with
 platelet-inhibitors

AU Dewanjee, M. K.; Fuster, V.; Kaye, M. P.; Josa, M.
 CS Mayo Clin. and Mayo Found., Rochester, MN, 55901, USA
 SO Radiopharm. 2, Proc. Int. Symp., 2nd (1979), 361-74. Editor(s): Sorenson,
 James A. Publisher: Soc. Nucl. Med., Inc., New York, N. Y.
 CODEN: 42GGAE

DT Conference
 LA English

L9 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1980:34129 CAPLUS
 DN 92:34129

TI Effect of risk factors and antirheumatic drugs on the proliferation of
 aortic wall cells

AU Hauss, W. H.; Mey, J.; Schulte, H.
 CS Inst. Arterioskleroseforsch., Univ. Muenster, Muenster, D-4400, Fed. Rep.
 Ger.

SO Atherosclerosis (Shannon, Ireland) (1979), 34(2), 119-43
 CODEN: ATHSBL; ISSN: 0021-9150

DT Journal
 LA English

L9 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1977:153559 CAPLUS
 DN 86:153559

TI Adenosine diphosphate-induced platelet aggregation in the states of
 hypercoagulability

AU Wang, Teh Y.; Hussey, Clara V.
 CS Dep. Pathol., Med. Coll. Wisconsin, Milwaukee, WI, USA
 SO Annals of Clinical and Laboratory Science (1977), 7(2), 152-7
 CODEN: ACLSCP; ISSN: 0091-7370

DT Journal
 LA English

L9 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1976:530521 CAPLUS
 DN 85:130521

TI Pharmaceutical preparations for prophylactic and therapeutic treatment of
 coronary heart diseases

IN Imhof, Peter R.
 PA Ciba-Geigy A.-G., Switz.
 SO Ger. Offen., 66 pp.
 CODEN: GWXXBX

DT Patent
 LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2600069	A1	19760715	DE 1976-2600069	19760102
	FR 2296430	A1	19760730	FR 1976-16	19760102
	FR 2296430	B1	19781110		
	CA 1063516	A1	19791002	CA 1976-242899	19760102

BE 837293	A1	19760705	BE 1976-163295	19760105
BE 837294	A1	19760705	BE 1976-163296	19760105
NL 7600045	A	19760708	NL 1976-45	19760105
ZA 7600026	A	19761229	ZA 1976-26	19760105
ZA 7600028	A	19761229	ZA 1976-28	19760105
AU 7610002	A1	19770714	AU 1976-10002	19760105
AU 499140	B2	19790405		
IL 48785	A1	19780831	IL 1976-48785	19760105
JP 51091337	A2	19760810	JP 1976-124	19760106
PRAI CH 1975-71	A	19750106		

L9 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2003 ACS
 AN 1973:119474 CAPLUS
 DN 78:119474
 TI Platelet renewal and the duration of inhibition of secondary platelet aggregation after a single dose of aspirin
 AU Boneu, B.; Bierme, R.; Boneu, A.; Guiraud, B.; Rascol, A.
 CS Cent. Reg. Transfus. Sanguine, Cent. Hop. Univ. Purpan, Toulouse, Fr.
 SO Pathologie Biologie (1972), 20(Suppl.), 71-5
 CODEN: PTBIAN; ISSN: 0369-8114
 DT Journal
 LA French

=> d his

(FILE 'HOME' ENTERED AT 10:19:37 ON 23 JAN 2003)

FILE 'REGISTRY' ENTERED AT 10:19:45 ON 23 JAN 2003

	E ASPRIN
	E ASPIRIN
L1	50 S E3
	E ATORVASTATIN
L2	8 S E2-E3

FILE 'CAPLUS' ENTERED AT 10:22:28 ON 23 JAN 2003

FILE 'REGISTRY' ENTERED AT 10:22:39 ON 23 JAN 2003

FILE 'CAPLUS' ENTERED AT 10:23:00 ON 23 JAN 2003

	E ATHEROSCLEROSIS
L3	33649 S E3
	E ARTERIOSCLEROSIS
L4	9906 S E1-E12
L5	16388 S L1
L6	725 S L2
L7	202 S L5 AND L3
L8	46 S L5 AND L4
L9	29 S L8 NOT L7

=> d 17 150-202

L7 ANSWER 150 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:183050 CAPLUS
 DN 118:183050
 TI Aspirin inhibits platelet activity but does not attenuate experimental **atherosclerosis**
 AU Sun, Yi Ping; Zhu, Bo Qing; Sievers, Richard E.; Isenberg, William M.; Parmley, William W.
 CS Cardiovasc. Res. Inst., Univ. California, San Francisco, CA, USA
 SO American Heart Journal (1993), 125(1), 79-86
 CODEN: AHJOA2; ISSN: 0002-8703

DT Journal
LA English

L7 ANSWER 151 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1993:45759 CAPLUS

DN 118:45759

TI Use of angiotensin-converting enzyme (ACE) inhibitors for lowering serum cholesterol

IN Aberg, A. K. Gunnar; Kowala, Mark; Ferrer, Patricia

PA Squibb, E. R., and Sons, Inc., USA

SO Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 508665	A2	19921014	EP 1992-302822	19920331
	EP 508665	A3	19931013		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	US 5157025	A	19921020	US 1991-677921	19910401
	CA 2064149	AA	19921002	CA 1992-2064149	19920326
	JP 05097679	A2	19930420	JP 1992-79608	19920401
PRAI	US 1991-677921		19910401		

L7 ANSWER 152 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1992:476481 CAPLUS

DN 117:76481

TI Method for preventing diabetic complications employing a cholesterol-lowering drug alone or in combination with an angiotensin-converting enzyme (ACE) inhibitor

IN Pan, Henry Y.; Bergman, Michael

PA Squibb, E. R., and Sons, Inc., USA

SO Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 482498	A2	19920429	EP 1991-117658	19911016
	EP 482498	A3	19931020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2052014	AA	19920420	CA 1991-2052014	19910923
	JP 04282324	A2	19921007	JP 1991-270853	19911018
PRAI	US 1990-599959		19901019		

L7 ANSWER 153 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1992:136250 CAPLUS

DN 116:136250

TI Pharmaceutical compositions and method for preventing, stabilizing or causing regression of **atherosclerosis** employing a combination of a cholesterol-lowering drug and an angiotensin-converting enzyme (ACE) inhibitor

IN Bergey, James L.; Kawano, James C.; Tschollar, Werner; Yonce, Cary S.

PA Squibb, E. R., and Sons, Inc., USA

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	EP 457514	A1	19911121	EP 1991-304232	19910510
	EP 457514	B1	19960821		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2040865	AA	19911116	CA 1991-2040865	19910419
	AU 9176270	A1	19911121	AU 1991-76270	19910426
	AU 651579	B2	19940728		
	ZA 9103509	A	19920226	ZA 1991-3509	19910508
	AT 141514	E	19960915	AT 1991-304232	19910510
	ES 2090244	T3	19961016	ES 1991-304232	19910510
	HU 57993	A2	19920128	HU 1991-1620	19910514
	HU 212102	B	19960228		
	JP 04226921	A2	19920817	JP 1991-110268	19910515
PRAI	US 1990-524266		19900515		
OS	MARPAT 116:136250				

L7 ANSWER 154 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1991:542256 CAPLUS

DN 115:142256

TI Pharmaceutical compositions containing HMG CoA reductase inhibitor and/or squalene synthetase inhibitor for treating peripheral atherosclerotic disease

IN Eisman, Martin

PA Squibb, E. R., and Sons, Inc., USA

SO Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 401705	A2	19901212	EP 1990-110475	19900601
	EP 401705	A3	19930107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2016467	AA	19901205	CA 1990-2016467	19900510
	AU 9054950	A1	19901206	AU 1990-54950	19900511
	HU 54059	A2	19910128	HU 1990-3320	19900604
	JP 03020226	A2	19910129	JP 1990-147164	19900605
	ZA 9004310	A	19910327	ZA 1990-4310	19900605
PRAI	US 1989-361520		19890605		
OS	MARPAT 115:142256				

L7 ANSWER 155 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1991:199344 CAPLUS

DN 114:199344

TI Aspirin reduces the growth of medial and neointimal thickenings in balloon-injured rat carotid arteries

AU Voelker, Wolfgang; Faber, Verona

CS Inst. Arterioscleros. Res., Univ. Muenster, Muenster, D-4400, Germany

SO Stroke (1990), 21(12, Suppl.), IV-44-IV-45

CODEN: SJCCA7; ISSN: 0039-2499

DT Journal

LA English

L7 ANSWER 156 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1991:22375 CAPLUS

DN 114:22375

TI Interleukin-4 (IL-4) in method and compositions for degradation and prevention of fibrin deposits associated with pathological conditions

IN Hamilton, John Allan; Hart, Prudence Hamilton

PA University of Melbourne, Australia

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9007932	A1	19900726	WO 1990-AU13	19900119
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2045574	AA	19900721	CA 1990-2045574	19900119
	AU 9049645	A1	19900813	AU 1990-49645	19900119
	AU 639903	B2	19930812		
	EP 454736	A1	19911106	EP 1990-902120	19900119
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04503062	T2	19920604	JP 1990-502488	19900119
	JP 06011706	B4	19940216		
	US 5236705	A	19930817	US 1991-720868	19910918
PRAI	AU 1989-2356		19890120		
	WO 1990-AU13		19900119		

L7 ANSWER 157 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1990:565161 CAPLUS

DN 113:165161

TI Prevention of myocardial lesions in JCR:LA-corpulent rats by nifedipine
AU Russell, James C.; Koeslag, Dorothy G.; Dolphin, Peter J.; Amy, Roger M.
CS Dep. Surg. Pathol., Univ. Alberta, Edmonton, AB, T6G 2G3, Can.
SO Arteriosclerosis (Dallas) (1990), 10(4), 658-64
CODEN: ARTRDW; ISSN: 0276-5047

DT Journal

LA English

L7 ANSWER 158 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1990:549899 CAPLUS

DN 113:149899

TI The oxidative modification of low-density lipoproteins by macrophages
AU Leake, David S.; Rankin, Sara M.
CS Div. Biomed. Sci., King's Coll. London, London, WC2R 2LS, UK
SO Biochemical Journal (1990), 270(3), 741-8
CODEN: BIJOAK; ISSN: 0306-3275

DT Journal

LA English

L7 ANSWER 159 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1990:196102 CAPLUS

DN 112:196102

TI Changes of adrenoceptor density in heart and brain and the reactivity of
isolated pulmonary artery ring in atherosclerotic rabbit
AU Zeng, Guiyun; Sun, Yading; Tian, Baohong; Wang, Zhong; Hu, Yanhua; An, Yan
CS Inst. Mater. Med., Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep.
China
SO Zhongguo Yaoli Xuebao (1990), 11(1), 18-21
CODEN: CYLPDN; ISSN: 0253-9756

DT Journal

LA Chinese

L7 ANSWER 160 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1989:592441 CAPLUS

DN 111:192441

TI Platelet-neutrophil-smooth muscle cell interactions: lipoxygenase-derived
mono- and dihydroxy acids activate cholesteryl ester hydrolysis by the
cyclic AMP dependent protein kinase cascade
AU Hajjar, David P.; Marcus, Aaron J.; Etingin, Orli R.

CS Med. Coll., Cornell Univ. Med. Coll., New York, NY, 10021, USA
 SO Biochemistry (1989), 28(22), 8885-91
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English

L7 ANSWER 161 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1989:437279 CAPLUS
 DN 111:37279
 TI Fatty acids, platelets and monocytes. Something to do with atherogenesis
 AU Oesterud, B.; Hansen, J. B.
 CS Inst. Med. Biol., Univ. Tromso, Tromso, Norway
 SO Annals of Medicine (Stockholm, Sweden) (1989), 21(1), 47-51
 CODEN: ANMDEU; ISSN: 0785-3890
 DT Journal
 LA English

L7 ANSWER 162 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1989:18333 CAPLUS
 DN 110:18333
 TI Diminished platelet residence time on active human atherosclerotic lesions
 in vivo - evidence for an optimal dose of aspirin?
 AU Sinzinger, H.; Kaliman, J.; Fitscha, P.; O'Grady, J.
 CS Dep. Nucl. Med., Univ. Vienna, Vienna, Austria
 SO Prostaglandins, Leukotrienes and Essential Fatty Acids (1988), 34(2),
 89-93
 CODEN: PLEAEU; ISSN: 0952-3278
 DT Journal
 LA English

L7 ANSWER 163 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:431853 CAPLUS
 DN 109:31853
 TI Effect of anticoagulant and antiplatelet drugs on in vitro smooth muscle
 cell proliferation
 AU Lindblad, Bengt; Burkell, William E.; Graham, Linda M.; Darvishian, David;
 Harrell, Karyn; Sell, Ruth; Stanley, James C.
 CS Med. Sch., Univ. Michigan, Ann Arbor, MI, USA
 SO Artery (Fulton, MI, United States) (1988), 15(4), 225-33
 CODEN: ARTEDR; ISSN: 0098-6127
 DT Journal
 LA English

L7 ANSWER 164 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:431848 CAPLUS
 DN 109:31848
 TI Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of
 platelet thrombus formation in stenosed canine coronary arteries
 AU Folts, John D.; Rowe, George G.
 CS Sect. Cardiol., Univ. Wisconsin Hosp., Madison, WI, 53792, USA
 SO Thrombosis Research (1988), 50(4), 507-16
 CODEN: THBRAA; ISSN: 0049-3848
 DT Journal
 LA English

L7 ANSWER 165 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:431846 CAPLUS
 DN 109:31846
 TI Effects of low-dose aspirin on endogenous eicosanoid formation in normal
 and atherosclerotic men
 AU Knapp, Howard R.; Healy, Cynthia; Lawson, John; FitzGerald, Garret A.
 CS Div. Clin. Pharmacol., Vanderbilt Univ., Nashville, TN, 37232, USA

SO Thrombosis Research (1988), 50(3), 377-86
 CODEN: THBRAA; ISSN: 0049-3848

DT Journal
 LA English

L7 ANSWER 166 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:404713 CAPLUS
 DN 109:4713
 TI Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin
 AU Moake, Joel L.; Turner, Nancy A.; Stathopoulos, Nikos A.; Nolasco, Leticia; Hellums, J. David
 CS Biomed. Eng. Lab., Rice Univ., Houston, TX, 77251, USA
 SO Blood (1988), 71(5), 1366-74
 CODEN: BLOOAW; ISSN: 0006-4971
 DT Journal
 LA English

L7 ANSWER 167 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:219504 CAPLUS
 DN 108:219504
 TI Experimental studies on vascular contraction induced by coagulation system and platelets. With special reference to **atherosclerosis**
 AU Kimura, Nobuhiko
 CS Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan
 SO Hyogo Ika Daigaku Igakkai Zasshi (1987), 12(1), 25-38
 CODEN: HIDZDO; ISSN: 0385-7638
 DT Journal
 LA Japanese

L7 ANSWER 168 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:130424 CAPLUS
 DN 108:130424
 TI Effect of dietary lipids on arterial thrombus formation: rationale for the support of drug therapy by diet
 AU Hornstra, Gerard
 CS Dep. Biochem., Limburg Univ., Maastricht, 6200 MD, Neth.
 SO Seminars in Thrombosis and Hemostasis (1988), 14(1), 59-65
 CODEN: STHMBV; ISSN: 0094-6176
 DT Journal; General Review
 LA English

L7 ANSWER 169 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1988:16117 CAPLUS
 DN 108:16117
 TI The effects of acetylsalicylic acid and tolbutamide on cultured human endothelial cells with special reference to prostacyclin synthesis analyzed by platelet aggregation
 AU Kawaguchi, Kenji
 CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
 SO Kumamoto Medical Journal (1987), 40(1), 37-44
 CODEN: KUMJAX; ISSN: 0023-5326
 DT Journal
 LA English

L7 ANSWER 170 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:568493 CAPLUS
 DN 107:168493
 TI The effect of antiplatelet drugs on graft **atherosclerosis** in rat heterotopic cardiac allografts
 AU Muskett, A.; Burton, N. A.; Eichwald, E. J.; Shelby, J.; Hendrickson, M.;

Sullivan, J. J.
 CS Sch. Med., Univ. Utah, Salt Lake City, UT, USA
 SO Transplantation Proceedings (1987), 19(4, Suppl. 5), 74-6
 CODEN: TRPPA8; ISSN: 0041-1345
 DT Journal
 LA English

L7 ANSWER 171 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:451201 CAPLUS
 DN 107:51201
 TI The role of arachidonic acid metabolites in cardiovascular homeostasis.
 Biochemical, histological and clinical cardiovascular effects of
 non-steroidal anti-inflammatory drugs and their interactions with
 cardiovascular drugs
 AU Goodman, DeWitt S.
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Drugs (1987), 33(Suppl. 1), 47-55
 CODEN: DRUGAY; ISSN: 0012-6667
 DT Journal; General Review
 LA English

L7 ANSWER 172 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:432862 CAPLUS
 DN 107:32862
 TI Surprising effects of the sequential administration of pentoxifylline and
 low dose acetylsalicylic acid on thrombus formation
 AU Seiffge, Dirk; Weithmann, K. Ulrich
 CS Hoechst A.-G., Wiesbaden, 6200/12, Fed. Rep. Ger.
 SO Thrombosis Research (1987), 46(2), 371-83
 CODEN: THBRAA; ISSN: 0049-3848
 DT Journal
 LA English

L7 ANSWER 173 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:18881 CAPLUS
 DN 106:18881
 TI Triterpenyl esters of organic acids and hypolipemic agents composed of
 them
 IN Kimura, Goro; Hirose, Yoshihiko; Yoshida, Kumi; Kuzuya, Fumio; Fujita,
 Katsunari
 PA Amano Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 260 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 166542	A2	19860102	EP 1985-303839	19850530
	EP 166542	A3	19860709		
	EP 166542	B1	19900808		
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 60258198	A2	19851220	JP 1984-115306	19840604
	JP 01040040	B4	19890824		
	JP 60258119	A2	19851220	JP 1984-115307	19840604
	JP 01040014	B4	19890824		
	JP 61243099	A2	19861029	JP 1985-85254	19850419
	JP 05033713	B4	19930520		
	JP 61243022	A2	19861029	JP 1985-85255	19850419
	CA 1265785	A1	19900213	CA 1985-481808	19850517
	AU 8543130	A1	19851212	AU 1985-43130	19850530
	AU 598724	B2	19900705		

	US 4748161	A	19880531	US 1985-739183	19850530
	FI 8502216	A	19851205	FI 1985-2216	19850603
	DK 8502469	A	19851205	DK 1985-2469	19850603
	NO 8502246	A	19851205	NO 1985-2246	19850603
	SU 1538892	A3	19900123	SU 1985-3913136	19850603
	ES 544466	A1	19870701	ES 1985-544466	19850604
	CN 85109752	A	19861217	CN 1985-109752	19851220
	US 4748161	B1	19911015	US 1990-90001980	19900404
PRAI	JP 1984-115306		19840604		
	JP 1984-115307		19840604		
	JP 1985-85254		19850419		
	JP 1985-85255		19850419		
	JP 1984-115406		19840604		
	US 1985-739183		19850530		
L7	ANSWER 174 OF 202 CAPLUS COPYRIGHT 2003 ACS				
AN	1984:483760 CAPLUS				
DN	101:83760				
TI	Effect of antiplatelet therapy on restenosis after experimental angioplasty				
AU	Faxon, David P.; Sanborn, Timothy A.; Haudenschild, Christian C.; Ryan, Thomas J.				
CS	Univ. Hosp., Boston Univ., Boston, MA, 02118, USA				
SO	American Journal of Cardiology (1984), 53(12), 72-6				
	CODEN: AJCDAG; ISSN: 0002-9149				
DT	Journal				
LA	English				
L7	ANSWER 175 OF 202 CAPLUS COPYRIGHT 2003 ACS				
AN	1984:207791 CAPLUS				
DN	100:207791				
TI	Cyclical abnormalities in the bactericidal function, superoxide production, and lysozyme activity of neutrophils obtained from a healthy woman during menstruation: reversal by pretreatment with aspirin				
AU	Berger, Elaine M.; Harada, Ruth N.; Vatter, Albert E.; Bowman, C. Michael; Repine, John E.				
CS	Health Sci. Cent., Univ. Colorado, Denver, CO, 80262, USA				
SO	Journal of Infectious Diseases (1984), 149(3), 413-19				
	CODEN: JIDIAQ; ISSN: 0022-1899				
DT	Journal				
LA	English				
L7	ANSWER 176 OF 202 CAPLUS COPYRIGHT 2003 ACS				
AN	1984:96410 CAPLUS				
DN	100:96410				
TI	Effect of various doses of aspirin on the development of experimental atherosclerosis				
AU	Berisha, Sali; Bocari, Gezim; Santo, Arben; Hasa, Donika				
CS	Univ. Tiranes, Tiranes, Albania				
SO	Buletin i Universitetit te Tiranes Enver Hoxha, Seria Shkencat Mjekesore (1983), 23(2), 103-8				
	CODEN: BUMJD5; ISSN: 0379-7643				
DT	Journal				
LA	Albanian				
L7	ANSWER 177 OF 202 CAPLUS COPYRIGHT 2003 ACS				
AN	1983:520209 CAPLUS				
DN	99:120209				
TI	Experimental studies on the mechanism of thrombus formation in hyperlipidemic and atherosclerotic rabbits				
AU	Suehiro, Akira				
CS	Dep. Intern. Med., Hyogo Coll. Med., Nishinomiya, 663, Japan				

SO Hyogo Ika Daigaku Igakkai Zasshi (1982), 7(2), 77-90
 CODEN: HIDZDO; ISSN: 0385-7638
 DT Journal
 LA Japanese

L7 ANSWER 178 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1983:482313 CAPLUS
 DN 99:82313
 TI Anti-proliferative effect of pyridinolcarbamate and of aspirin in the
 early stages of atherogenesis in swine
 AU Kim, D. N.; Lee, K. T.; Schmee, J.; Thomas, W. A.
 CS Dep. Pathol., Albany Med. Coll., Albany, NY, 12208, USA
 SO Atherosclerosis (Shannon, Ireland) (1983), 48(1), 1-13
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English

L7 ANSWER 179 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1983:416261 CAPLUS
 DN 99:16261
 TI Experimental evaluation of venosclerosis of aortocoronary femoral vein
 bypass graft in control and aspirin-persantine-treated dogs: correlation
 with **atherosclerosis**
 AU Dewanjee, Mrinal K.
 CS Radiopharm. Lab., Mayo Clin., Rochester, MN, USA
 SO Radiat. Cell. Response, Rep. John Lawrence Interdiscip. Symp. Phys.
 Biomed. Sci., 2nd (1983), Meeting Date 1981, 61-82. Editor(s): Scott,
 George P.; Wahner, Heinz W. Publisher: Iowa State Univ. Press, Ames, Iowa.
 CODEN: 49OAAH
 DT Conference
 LA English

L7 ANSWER 180 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:538426 CAPLUS
 DN 97:138426
 TI Prevention of lipid accumulation in experimental vein bypass grafts by
 antiplatelet therapy
 AU Bonchek, Lawrence I.; Boerboom, Lawrence E.; Olinger, Gordon N.; Pepper,
 John R.; Munns, James; Hutchinson, Lawrence; Kissebah, Ahmed H.
 CS Dep. Cardiothor. Surgery Med., Med. Coll. Wisconsin, Milwaukee, WI, USA
 SO Circulation (1982), 66(2), 338-41
 CODEN: CIRCAZ; ISSN: 0009-7322
 DT Journal
 LA English

L7 ANSWER 181 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:210581 CAPLUS
 DN 96:210581
 TI Comparison of the effects of aspirin and indomethacin on aortic
 atherogenesis induced in rabbits
 AU Jouve, Remy; Juhan-Vague, Irene; Aillaud, Marie Françoise; Serment-Jouve,
 Marie Pierre; Payan, Henri
 CS Sch. Med., Univ. Marseille, Marseille, Fr.
 SO Atherosclerosis (Shannon, Ireland) (1982), 42(2-3), 319-21
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English

L7 ANSWER 182 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:155256 CAPLUS
 DN 96:155256
 TI Effect of aspirin on cholesterol-induced platelet activation in rabbits

AU Splawinski, J.; Corell, T.; Hasselmann, G.; Mruk, J.
CS Dep. Pharmacol., Dumex, Copenhagen, DK-2300, Den.
SO Thrombosis Research (1982), 25(1-2), 155-61
CODEN: THBRAA; ISSN: 0049-3848
DT Journal
LA English

L7 ANSWER 183 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1982:155205 CAPLUS
DN 96:155205
TI The effect of low-dose aspirin and dipyridamole upon
atherosclerosis in the rabbit
AU Koster, J. K., Jr.; Tryka, A. F.; H'Doubler, P.; Collins, J. J., Jr.
CS Dep. Surg., Harvard Med. Sch., Boston, MA, 02115, USA
SO Artery (Fulton, MI, United States) (1981), 9(6), 405-13
CODEN: ARTEDR; ISSN: 0098-6127
DT Journal
LA English

L7 ANSWER 184 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1982:135752 CAPLUS
DN 96:135752
TI Enhancement of experimental **atherosclerosis** by aspirin
AU Debons, Albert F.; Fani, Kazem; Jimenez, Fidelio A.
CS VA Med. Cent., State University New York, Brooklyn, NY, USA
SO Journal of Toxicology and Environmental Health (1981), 8(5-6), 899-906, 1
plate
CODEN: JTEHD6; ISSN: 0098-4108
DT Journal
LA English

L7 ANSWER 185 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1982:46039 CAPLUS
DN 96:46039
TI Evaluation of the effect of acetylsalicylic acid on the thromboplastin
activity of human erythrocytes
AU Ashkinazi, I. Ya.
CS USSR
SO Deposited Doc. (1980), VINITI 3752-80, 14 pp. Avail.: VINITI
DT Report
LA Russian

L7 ANSWER 186 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1981:597384 CAPLUS
DN 95:197384
TI Endothelial damage induced by polyethylene catheter in the rat
AU Vilageliu, J.; Arano, A.; Bruseghini, L.
CS Spain
SO Methods and Findings in Experimental and Clinical Pharmacology (1981),
3(5), 279-81
CODEN: MFEPDX; ISSN: 0379-0355
DT Journal
LA English

L7 ANSWER 187 OF 202 CAPLUS COPYRIGHT 2003 ACS
AN 1981:564988 CAPLUS
DN 95:164988
TI Studies of human platelet .alpha.-granule release in vivo
AU Files, Joe C.; Malpass, Thomas W.; Yee, Esther K.; Ritchie, James L.;
Harker, Laurence A.
CS Sch. Med., Univ. Washington, Seattle, WA, USA
SO Blood (1981), 58(3), 607-18

CODEN: BLOOAW; ISSN: 0006-4971

DT Journal
LA English

L7 ANSWER 188 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1981:490646 CAPLUS

DN 95:90646

TI The effect of platelet regulatory drugs in experimental models of thrombosis, **atherosclerosis** and myocardial ischemia

AU White, A. M.; Butler, K. D.

CS Ciba-Geigy Pharm. Div., Horsham/West Sussex, RH12 4 AB, UK

SO Clin. Pharmacol. Ther. Proc. Plenary Lect., Symp. Ther. Sess. World Conf., 1st (1980), 213-23. Editor(s): Turner, Paul. Publisher: Macmillan, London, Engl.

CODEN: 46BIAN

DT Conference; General Review

LA English

L7 ANSWER 189 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1981:400037 CAPLUS

DN 95:37

TI AAS and Anturan: their effects on the clinical complications of **atherosclerosis**

AU Packhama, M. A.; Mustard, J. F.

CS Dep. Biochim., Univ. Toronto, Toronto, ON, Can.

SO Medecine Moderne du Canada (1981), 36(4), 453-8

CODEN: MMCNAT; ISSN: 0025-6803

DT Journal; General Review

LA French

L7 ANSWER 190 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1981:167566 CAPLUS

DN 94:167566

TI A new approach to the treatment of **atherosclerosis** and trapidil as an antagonist to platelet-derived growth factor

AU Ohnishi, H.; Yamaguchi, K.; Shimada, S.; Suzuki, Y.; Kumagai, A.

CS Tokyo Res. Lab., Mochida Pharm. Co., Ltd., Tokyo, 115, Japan

SO Life Sciences (1981), 28(14), 1641-6

CODEN: LIFSAK; ISSN: 0024-3205

DT Journal

LA English

L7 ANSWER 191 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1981:96215 CAPLUS

DN 94:96215

TI Platelets, sulfinpyrazone and organ graft rejection

AU Jamieson, Stuart W.; Burton, Nelson A.; Reitz, Bruce A.

CS Dep. Cardiovasc. Surg., Stanford Univ. Hosp., Stanford, CA, USA

SO Cardiovasc. Actions Sulfinpyrazone: Basic Clin. Res., Proc. Int. Symp. (1980), Meeting Date 1979, 229-47. Editor(s): McGregor, Maurice; Mustard, J. Fraser; Oliver, Michael F. Publisher: Symp. Spec., Miami, Fla.

CODEN: 45CDA6

DT Conference

LA English

L7 ANSWER 192 OF 202 CAPLUS COPYRIGHT 2003 ACS

AN 1981:58302 CAPLUS

DN 94:58302

TI The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine

AU Clopath, P.

CS Pharm. Div., CIBA-GEIGY Ltd., Basel, CH-4002, Switz.

SO British Journal of Experimental Pathology (1980), 61(4), 440-3
 CODEN: BJEPAS; ISSN: 0007-1021
 DT Journal
 LA English

L7 ANSWER 193 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:413847 CAPLUS
 DN 91:13847
 TI Aspirin inhibits development of coronary **atherosclerosis** in
 cynomolgus monkeys (*Macaca fascicularis*) fed an atherogenic diet
 AU Pick, Ruth; Chediak, Juan; Glick, Gerald
 CS Cardiovasc. Inst., Michael Reese Hosp., Chicago, IL, 60616, USA
 SO Journal of Clinical Investigation (1979), 63(1), 158-62
 CODEN: JCINAO; ISSN: 0021-9738
 DT Journal
 LA English

L7 ANSWER 194 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:180165 CAPLUS
 DN 90:180165
 TI Studies on the progression and regression of coronary and peripheral
atherosclerosis in the cynomolgus monkey. I. Effects of
 dipyridamole and aspirin
 AU Hollander, William; Kirkpatrick, Barbara; Paddock, John; Colombo, Marilyn;
 Nagraj, Siva; Prusty, Somnath
 CS Med. Cent., Boston Univ., Boston, MA, USA
 SO Experimental and Molecular Pathology (1979), 30(1), 55-73
 CODEN: EXMPA6; ISSN: 0014-4800
 DT Journal
 LA English

L7 ANSWER 195 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1979:145804 CAPLUS
 DN 90:145804
 TI Anti-inflammatory drugs in experimental **atherosclerosis**. Part
 4. Inhibition of **atherosclerosis** in vivo and thromboxane
 synthesis and platelet aggregation in vitro
 AU Bailey, J. Martyn; Makheja, A. N.; Butler, Jean; Salata, K.
 CS Sch. Med. Health Sci., George Washington Univ., Washington, DC, USA
 SO Atherosclerosis (Shannon, Ireland) (1979), 32(2), 195-203
 CODEN: ATHSBL; ISSN: 0021-9150
 DT Journal
 LA English


L7 ANSWER 196 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1977:527635 CAPLUS
 DN 87:127635
 TI The possible antithromboplastic effect of aspirin. Preliminary
 communication
 AU Dincol, Koray; Ozkan, Emir; Oner, Adil; Okur, Omer; Ekmekci, Ali;
 Buyukozturk, Kemalettin; Ozcan, Remzi
 CS Dep. Intern. Med., Istanbul Fac. Med., Istanbul, Turk.
 SO Medical Bulletin of Istanbul Medical Faculty (Istanbul University) (1976),
 9(1), 11-15
 CODEN: MBIFDT; ISSN: 0378-6358
 DT Journal
 LA English

L7 ANSWER 197 OF 202 CAPLUS COPYRIGHT 2003 ACS
 AN 1977:187267 CAPLUS
 DN 86:187267
 TI Platelet and fibrinogen survival in coronary **atherosclerosis**.

AN 1986:147555 CAPLUS
 DN 104:147555
 TI Effects of vitamin C and E, trace element selenium and brown sugar in
 guinea pig arteriosclerosis
 AU Sun, Yuming; Lu, Tianluan; Gao, Jianzhong; Dou, Shulan; Wang, Hong; Sun,
 Shuqin; Li, Tianyang; Sun, Rui
 CS Peop. Rep. China
 SO Tianjin Yiyao (1985), 13(10), 615-17
 CODEN: TIYADG; ISSN: 0253-9896
 DT Journal
 LA Chinese
 CC 18-1 (Animal Nutrition)
 AB Dietary vitamin C [50-81-7] and E [1406-18-4], Se, and brown sugar
 decreased the incidence of arteriosclerosis induced by cholesterol (0.1
 g/day) in guinea pig. In the exptl. animal diets, the supplementary amts.
 were 1.5 mg vitamin C, 1.5 mg vitamin E, 35 .mu.g Na2SeO3, and 2 g brown
 sugar/day/animal. Vitamin C showed the strongest effect on inhibition of
 arteriosclerosis. The extents of fatty liver and peroxy fatty acids were
 also decreased by the inhibitory agents.
 ST atherosclerosis vitamin selenium sugar diet; liver lipid atherosclerosis
 inhibitor diet
 IT Lipids, biological studies
 RL: BIOL (Biological study)
 (dietary atherosclerosis inhibitors effect on, of liver)
 IT Atherosclerosis
 (inhibition of, dietary vitamin C and E and brown sugar in)
 IT Liver, composition
 (lipids and peroxy fatty acids of, dietary atherosclerosis inhibitors
 effect on)
 IT Fatty acids, biological studies
 RL: BIOL (Biological study)
 (peroxy, dietary atherosclerosis inhibitors effect on, of liver)
 IT 50-81-7, biological studies 1406-18-4 7782-49-2, biological studies
 RL: BIOL (Biological study)
 (atherosclerosis inhibition by dietary)
 IT 57-50-1, biological studies
 RL: BIOL (Biological study)
 (brown, atherosclerosis inhibition by dietary)

=>

AN 1979:413847 CAPLUS
 DN 91:13847
 TI Aspirin inhibits development of coronary **atherosclerosis** in
 cynomolgus monkeys (*Macaca fascicularis*) fed an atherogenic diet
 AU Pick, Ruth; Chediak, Juan; Glick, Gerald
 CS Cardiovasc. Inst., Michael Reese Hosp., Chicago, IL, 60616, USA
 SO Journal of Clinical Investigation (1979), 63(1), 158-62
 CODEN: JCINAO; ISSN: 0021-9738
 DT Journal
 LA English
 CC 1-5 (Pharmacodynamics)
 GI



AB In monkeys fed an atherogenic diet, aspirin (I) [50-78-2] (81
 mg/monkey/day) did not affect plasma cholesterol [57-88-5] levels or
 aortic **atherosclerosis**. Platelet aggregation induced by
 arachidonic acid was almost completely suppressed. I decreased
 significantly the no. of coronary vessels with atherosclerotic involvement
 and the no. of coronary vessels narrowed by 20% or more. Thus, I appears
 to exert a protective effect in the primary prevention of diet-induced
 coronary **atherosclerosis** in a primate model.
 ST aspirin coronary **atherosclerosis** prevention
 IT **Atherosclerosis**
 (coronary, aspirin prevention of)
 IT 50-78-2
 RL: BIOL (Biological study)
 (coronary **atherosclerosis** prevention by)
 IT 57-88-5, biological studies
 RL: BIOL (Biological study)
 (of blood plasma, aspirin effect on)

(15) Ubbink, J; J Chromatogr 1991, V565, P441 CAPLUS

L12 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS

AN 1998:484927 CAPLUS

DN 129:127177

TI Pharmaceutical preparations of glutathione and methods of administration

IN Demopoulos, Harry B.; Seligman, Myron L.

PA Antioxidant Pharmaceuticals Corp., USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-20

ICS A61K009-48

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W:			AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9856205	A1	19980731	AU 1998-56205	19971231
	EP 957901	A1	19991124	EP 1997-952640	19971231
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	
	JP 2001507696	T2	20010612	JP 1998-530206	19971231
	US 6350467	B1	20020226	US 1999-331947	19990628
	US 2002136763	A1	20020926	US 2002-83327	20020225
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		
AB	A method of increasing glutathione levels in mammalian cells comprises administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.				
ST	glutathione capsule oral bolus therapeutic				
IT	Intestine, disease (Crohn's; glutathione pharmaceutical prepns. and methods of administration)				
IT	Injury (acute; glutathione pharmaceutical prepns. and methods of administration)				
IT	Respiratory distress syndrome (adult; glutathione pharmaceutical prepns. and methods of administration)				
IT	Glycosides RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (amino; glutathione pharmaceutical prepns. and methods of administration)				
IT	Gases (atm., toxic; glutathione pharmaceutical prepns. and methods of administration)				
IT	Drug delivery systems (capsules; glutathione pharmaceutical prepns. and methods of				

administration)

IT Catecholamines, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (catecholamine-related toxicity; glutathione pharmaceutical preps. and
 methods of administration)

IT Intestine
 (duodenum; glutathione pharmaceutical preps. and methods of
 administration)

IT Heart, disease
 (failure; glutathione pharmaceutical preps. and methods of
 administration)

IT Lung, disease
 (fibrosis; glutathione pharmaceutical preps. and methods of
 administration)

IT Drug delivery systems
 (gels; glutathione pharmaceutical preps. and methods of
 administration)

IT AIDS (disease)
 Alzheimer's disease
 Antioxidants
 Antitumor agents
 Antiviral agents
 Asbestosis
Atherosclerosis
 Cardiovascular agents
 Cataract
 Diabetes mellitus
 Drug delivery systems
 Emphysema
 Glaucoma (disease)
 Hepatitis
 Herpesviridae
 Human herpesvirus
 Ionizing radiation
 Liver
 Melanoma
 Mononuclear cell (leukocyte)
 Parkinson's disease
 Pharmacokinetics
 Rabies virus
 Radiotherapy
 Reducing agents
 Stomach
 Toxicants
 Toxicity
 Vasoconstriction
 (glutathione pharmaceutical preps. and methods of administration)

IT CD4 (antigen)
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (glutathione pharmaceutical preps. and methods of administration)

IT Glycation
 (glycated enzymes; glutathione pharmaceutical preps. and methods of
 administration)

IT Enzymes, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (glycated; glutathione pharmaceutical preps. and methods of
 administration)

IT Hydrocarbons, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (halo, toxicity; glutathione pharmaceutical preps. and methods of

administration)

IT Oxidation
(homolytic; glutathione pharmaceutical preps. and methods of administration)

IT Intestine
(ileum; glutathione pharmaceutical preps. and methods of administration)

IT Human immunodeficiency virus
RNA viruses
Retroviridae
(infection; glutathione pharmaceutical preps. and methods of administration)

IT Intestine, disease
(inflammatory; glutathione pharmaceutical preps. and methods of administration)

IT Brain, disease
Eye, disease
Eye, disease
Spinal cord
(injury; glutathione pharmaceutical preps. and methods of administration)

IT Eye, disease
(macula, degeneration; glutathione pharmaceutical preps. and methods of administration)

IT Metals, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(metal-ion toxicity; glutathione pharmaceutical preps. and methods of administration)

IT Drug delivery systems
(oral; glutathione pharmaceutical preps. and methods of administration)

IT Radicals, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(oxidn.; glutathione pharmaceutical preps. and methods of administration)

IT Drug delivery systems
(pellets, enteric-coated; glutathione pharmaceutical preps. and methods of administration)

IT Nerve, disease
(peripheral neuropathy; glutathione pharmaceutical preps. and methods of administration)

IT Alcohols, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxic; glutathione pharmaceutical preps. and methods of administration)

IT Actinides
Transuranium elements
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity; glutathione pharmaceutical preps. and methods of administration)

IT Intestine, disease
(ulcerative colitis; glutathione pharmaceutical preps. and methods of administration)

IT Drug delivery systems
(urethral insert; glutathione pharmaceutical preps. and methods of administration)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(viral, redn. of; glutathione pharmaceutical preps. and methods of administration)

IT Blood products
 Body fluid
 (virus inactivation in; glutathione pharmaceutical prepsns. and methods of administration)

IT 64-17-5, Ethanol, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (glutathione pharmaceutical prepsns. and methods of administration)

IT 103-90-2, Acetaminophen
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glutathione pharmaceutical prepsns. and methods of administration)

IT 70-18-8, Glutathione, biological studies
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (glutathione pharmaceutical prepsns. and methods of administration)

IT 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 57564-91-7, Nitrosoglutathione
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glutathione pharmaceutical prepsns. and methods of administration)

IT 50-99-7, D-Glucose, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process) (glutathione pharmaceutical prepsns. and methods of administration)

IT 10102-43-9, Nitric oxide, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (glutathione pharmaceutical prepsns. and methods of administration)

IT 495-27-2, Ophthalmic acid
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative) (glutathione pharmaceutical prepsns. and methods of administration)

IT 50-53-3, Chlorpromazine, biological studies 50-78-2, Aspirin 50-81-7, Ascorbic acid, biological studies 57-92-1, Streptomycin, biological studies 59-02-9D, .alpha.-Tocopherol, esters 74-79-3, L-Arginine, biological studies 500-38-9 1403-66-3, Gentamycin 1404-04-2, Neomycin 8063-07-8, Kanamycin 32385-11-8 32986-56-4, Tobramycin 37311-39-0, Vitamin E succinate 37517-28-5, Amikacin 56391-56-1, Netilmicin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glutathione pharmaceutical prepsns. and methods of administration)

IT 7439-89-6, Iron, biological studies 7439-92-1, Lead, biological studies 7439-97-6, Mercury, biological studies 7440-43-9, Cadmium, biological studies 7440-50-8, Copper, biological studies 7782-49-2, Selenium, biological studies 13494-80-9, Tellurium, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (toxicity; glutathione pharmaceutical prepsns. and methods of administration)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Demopoulos; US 5204114 A 1993 CAPLUS
- (2) Nagasawa; US 5624955 A 1997 CAPLUS
- (3) Naylor; US 4414212 A 1983 CAPLUS

L12 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS


AN 1994:163728 CAPLUS

DN 120:163728

TI Amines (phenoxyalkylamines) as inhibitors of squalene synthase and their preparation and pharmaceutical compositions

IN Brown, George Robert; Eakin, Murdoch Allan; Mallion, Keith Blakeney;
 Harrison, Peter John
 PA Harrison, Alison, UK; Zeneca Ltd.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-135
 CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320807	A1	19931028	WO 1993-GB742	19930408
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2093777	AA	19931010	CA 1993-2093777	19930408
	AU 9339005	A1	19931118	AU 1993-39005	19930408
	EP 589018	A1	19940330	EP 1993-908009	19930408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06511259	T2	19941215	JP 1993-518098	19930408
	US 5866611	A	19990202	US 1994-157204	19940519
PRAI	GB 1992-7855		19920409		
	WO 1993-GB742		19930408		
OS	MARPAT 120:163728				
GI					



III

AB Use of amines ROANR1R2 [I; R = (un)substituted Ph; A = (CH2)3 optionally substituted by .gtoreq.1 C1-4 alkyl group(s); R1, R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl, alkenyl; or R1R2 = atoms to form certain heterocycles] and salts to manuf. medicaments for treating diseases (esp. hypercholesterolemia or **atherosclerosis**) via inhibition of squalene synthase (II) is claimed. Over 120 synthetic examples are listed, and 4 std. formulations are given. For example, etherification of 4-acetamido-2-allylphenol with Br(CH2)3Br and amination of the monobromide product with iso-PrNH2 gave title compd. III (Y2 = allyl), isolated as the HBr salt. I significantly inhibited II in vitro at 0.001-50 .mu.M, and inhibited cholesterol biosynthesis in rats at 0.1-100 mg/kg, e.g., with ED50 of 27 mg/kg for III.HCl (Y2 = Pr).

ST phenoxyalkylamine prepn squalene synthase inhibitor; amine phenoxyalkyl prepn squalene synthase inhibitor; antihypercholesterolemic phenoxyalkylamine prepn; antiatherosclerotic phenoxyalkylamine prepn

IT Anticholesteremics and Hypolipemics
 (phenoxyalkylamines1)

IT Antiarteriosclerotics
 (antiatherosclerotics, phenoxyalkylamines)

IT 100-58-3, Phenylmagnesium bromide 925-90-6, Ethylmagnesium bromide 152719-52-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (Grignard reaction of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 75-04-7, Ethylamine, reactions 75-64-9, tert-Butylamine, reactions
 100-46-9, Benzylamine, reactions 107-10-8, Propylamine, reactions
 109-73-9, Butylamine, reactions 124-40-3, Dimethylamine, reactions
 624-78-2, Ethylmethylaniline 4747-21-1, Isopropylmethylaniline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (alkylation of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 75-31-0, Isopropylamine, reactions 107-11-9, Allylamine 108-18-9,
 Diisopropylamine 108-91-8, Cyclohexylamine, reactions 110-91-8,
 Morpholine, reactions 123-75-1, Pyrrolidine, reactions 765-30-0,
 Cyclopropylamine 1003-03-8, Cyclopentylamine 2516-34-9,
 Cyclobutylamine 5452-35-7, Cycloheptylamine 7664-41-7, Ammonia,
 reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (alkylation of, in prepn. of phenoxyalkylamines as drugs)

IT 99-93-4 123-08-0, 4-Hydroxybenzaldehyde 403-14-5, 3-Fluoro-4-
 hydroxyacetophenone 2709-93-5 98619-07-9, 4-Acetyl-3-fluorophenol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (allylation of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 106-31-0, Butyric anhydride 108-24-7, Acetic anhydride 123-62-6,
 Propionic anhydride 5930-28-9, 4-Amino-2,6-dichlorophenol 152719-51-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 109-89-7, Diethylamine, reactions
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amidation or alkylation of, in prepn. of phenoxyalkylamine derivs. as
 drugs)

IT 57-88-5P, Cholesterol, biological studies
 RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (biosynthesis of, squalene synthase-inhibiting phenoxyalkylamines
 effect on)

IT 95-56-7, 2-Bromophenol 95-57-8, 2-Chlorophenol 608-33-3,
 2,6-Dibromophenol 4812-20-8, 2-Isopropoxyphenol 18448-88-9,
 2-Crotylphenol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (conversion to acetamido deriv., in prepn. of phenoxyalkylamine derivs.
 as drugs)

IT 18448-88-9, 2-(2-Butenyl)phenol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (conversion to amino deriv., in prepn. of phenoxyalkylamine derivs. as
 drugs)

IT 121-57-3, Sulfanilic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (diazotization and reaction with benzylphenol, in prepn. of
 phenoxyalkylamines as drugs)

IT 90-43-7, 2-Phenylphenol 107-80-2, 1,3-Dibromobutane 591-20-8,
 3-Bromophenol 3769-41-3, 3-Benzoyloxyphenol 6974-77-2,
 1-Bromo-3-chloro-2-methylpropane
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (etherification of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 87-86-5, Pentachlorophenol 88-69-7, 2-Isopropylphenol 89-83-8,
 2-Isopropyl-5-methylphenol 92-69-3, 4-Phenylphenol 94-18-8,
 4-(Benzoyloxycarbonyl)phenol 95-77-2, 3,4-Dichlorophenol 103-16-2,
 4-Benzoyloxyphenol 103-90-2, 4-Acetamidophenol 106-41-2,
 4-Bromophenol 106-95-6, Allyl bromide, reactions 109-54-6,
 3-Dimethylaminopropyl chloride 109-64-8, 1,3-Dibromopropane 118-61-6,
 2-Ethoxycarbonylphenol 583-78-8, 2,5-Dichlorophenol 644-35-9,
 2-Propylphenol 771-61-9, Pentafluorophenol 831-82-3, 4-Phenoxyphenol
 1009-11-6, 4-Butanoylphenol 1073-29-6, 2-(Methylmercapto)phenol
 1132-05-4, 2-Allyl-4-acetylphenol 1458-98-6, 2-Methylallyl bromide

1745-81-9, 2-Allylphenol 2078-54-8, 2,6-Diisopropylphenol 3463-03-4, 3-(Methylmercapto)phenol 5460-29-7, N-(3-Bromopropyl)phthalimide
13997-72-3, 2-Allyl-4-fluorophenol 17044-70-1, 4-Acetyl-2,6-dichlorophenol 25804-49-3, 4-(tert-Butoxycarbonyl)phenol 42873-96-1, 4-Cyclohexyloxyphenol 55815-20-8, 2,4-Dibromo-6-phenylphenol
59086-51-0, 2-Allyl-4-ethoxycarbonylphenol 80508-10-7, 2-Geranylphenol
142860-21-7, 2-Allyl-4-butoxyphenol 152719-49-8 152719-57-8, 4-Butoxy-2-propylphenol 152719-58-9, 4-Acetamido-2-propylphenol
152719-59-0, 2-Allyl-5-methoxy-4-propionylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification of, in prepn. of phenoxyalkylamines as drugs)

IT 120-47-8, 4-Ethoxycarbonylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification or amidation of, in prepn. of phenoxyalkylamines as drugs)

IT 87-65-0, 2,6-Dichlorophenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification or conversion to acetamido deriv., in prepn. of phenoxyalkylamine derivs. as drugs)

IT 122-94-1, 4-Butoxyphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification or formylation of, in prepn. of phenoxyalkylamines as drugs)

IT 28994-41-4, 2-Benzylphenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification or reaction with diazotized sulfanilic acid, in prepn. of phenoxyalkylamines as drugs)

IT 106-48-9, p-Chlorophenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification with acrylonitrile, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 107-13-1, Acrylonitrile, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification with chlorophenol, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 9077-14-9, Squalene synthase
RL: RCT (Reactant); RACT (Reactant or reagent)
(inhibitors of, prepn. of phenoxyalkylamines as)

IT 619-08-9, 2-Chloro-4-nitrophenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(iron redn. of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 95-46-5, 2-Bromotoluene
RL: RCT (Reactant); RACT (Reactant or reagent)
(lithiation and reaction with tri-Me borate, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 1073-72-9, 4-(Methylmercapto)phenol
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidn. or etherification of, in prepn. of phenoxyalkylamines as drugs)

IT 593-56-6, Methoxyamine hydrochloride 3332-29-4, Ethoxyamine hydrochloride 5470-11-1, Hydroxylamine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(oximation by, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 98-80-6, Phenylboronic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(phenylation of aryl bromide by, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 152719-53-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(phenylation of, in prepn. of phenoxyalkylamine derivs. as drugs)

IT 3964-52-1P, 2-Chloro-4-aminophenol 3964-54-3P, 4-Acetamido-2-chlorophenol 6329-78-8P, 4-Acetamido-2-bromophenol 6622-73-7P, 4-Acetamido-1-allyloxybenzene 14763-60-1P, 4-Methylsulfonylphenol

16419-60-6P, 2-Methylphenylboronic acid 21424-62-4P,
 2-Allyl-4-phenylphenol 24544-15-8P, 2-Allyl-4-propanamidophenol
 29121-32-2P, 2-Allyl-4-(aminocarbonylmethyl)phenol 29973-52-2P,
 2-Benzyl-4-propionamidophenol 31011-02-6P 41002-38-4P,
 2-Hydroxy-5-butoxybenzaldehyde 41052-88-4P, 3-Allyl-4-
 hydroxybenzaldehyde 46125-42-2P, 3-(4-Chlorophenoxy)propionitrile
 63558-07-6P, 4-Acetamido-2,6-dibromophenol 79119-31-6P,
 4-Hydroxy-N,N-diethylbenzamide 79694-26-1P, 4-Acetamido-2,6-
 dichlorophenol 84176-62-5P, 4-Acetamido-2-allylphenol 90816-84-5P
 90923-69-6P, 2-Allyl-4-cyanophenol 91496-09-2P, 2-Allyl-4-
 propionylphenol 97023-54-6P, 2-Allyl-4-butanoylphenol 99186-54-6P
 100883-30-5P 142860-21-7P, 2-Allyl-4-butoxyphenol 152719-41-0P
 152719-42-1P 152719-43-2P 152719-44-3P 152719-45-4P 152719-46-5P
 152719-47-6P 152719-48-7P 152719-54-5P, 2-Allyl-(3'-
 bromopropoxy)benzene 152719-55-6P, N-Isopropyl-3-(3-
 bromophenoxy)propylamine 152719-56-7P, N,N-Diethyl-3-(3-
 benzyloxyphenoxy)propylamine 152974-06-6P 152974-07-7P,
 2-Allyl-4-sulfamoylphenol 152974-08-8P, 2-Allyl-4-(N-
 methylacetamido)phenol 152974-09-9P, 2-Allyl-4-butanamidophenol
 152974-10-2P, 2-Allyl-4-benzamidophenol 152974-11-3P,
 2-Allyl-4-(tert-butylcarbonylamino)phenol 152974-12-4P,
 2-Allyl-4-butoxycarbonylphenol 152974-13-5P, 4-Acetamido-2-
 isopropoxyphenol 152974-14-6P, 4-Acetamido-2-crotylphenol
 152974-15-7P, 4-Amino-2-(but-2-en-1-yl)phenol 152974-16-8P,
 4-Butyramido-2,6-dichlorophenol 152974-17-9P, 3-Allyl-5-fluoro-4-
 hydroxyacetophenone

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as intermediate for squalene synthase inhibitors)

IT	2084-22-2P	50911-60-9P	79611-72-6P	100840-61-7P	100840-99-1P
	125849-13-0P	152719-51-2P	152972-64-0P	152972-65-1P	152972-66-2P
	152972-67-3P	152972-69-5P	152972-70-8P	152972-71-9P	152972-72-0P
	152972-73-1P	152972-74-2P	152972-75-3P	152972-76-4P	152972-77-5P
	152972-78-6P	152972-79-7P	152972-80-0P	152972-81-1P	152972-82-2P
	152972-84-4P	152972-85-5P	152972-87-7P	152972-88-8P	152972-89-9P
	152972-90-2P	152972-91-3P	152972-93-5P	152972-94-6P	152972-95-7P
	152972-96-8P	152972-97-9P	152972-98-0P	152972-99-1P	152973-00-7P
	152973-01-8P	152973-02-9P	152973-03-0P	152973-04-1P	152973-06-3P
	152973-08-5P	152973-09-6P	152973-10-9P	152973-11-0P	152973-13-2P
	152973-14-3P	152973-16-5P	152973-17-6P	152973-18-7P	152973-19-8P
	152973-20-1P	152973-21-2P	152973-22-3P	152973-23-4P	152973-24-5P
	152973-25-6P	152973-27-8P	152973-29-0P	152973-30-3P	152973-31-4P
	152973-32-5P	152973-33-6P	152973-34-7P	152973-35-8P	152973-37-0P
	152973-38-1P	152973-39-2P	152973-40-5P	152973-41-6P	152973-42-7P
	152973-43-8P	152973-44-9P	152973-45-0P	152973-46-1P	152973-47-2P
	152973-48-3P	152973-49-4P	152973-51-8P	152973-53-0P	152973-54-1P
	152973-56-3P	152973-57-4P	152973-58-5P	152973-60-9P	152973-61-0P
	152973-62-1P	152973-63-2P	152973-64-3P	152973-66-5P	152973-67-6P
	152973-68-7P	152973-69-8P	152973-70-1P	152973-71-2P	152973-72-3P
	152973-73-4P	152973-74-5P	152973-75-6P	152973-76-7P	152973-77-8P
	152973-78-9P	152973-79-0P	152973-80-3P	152973-81-4P	152973-82-5P
	152973-83-6P	152973-84-7P	152973-85-8P	152973-86-9P	152973-87-0P
	152973-89-2P	152973-90-5P	152973-91-6P	152973-92-7P	152973-93-8P
	152973-94-9P	152973-95-0P	152973-96-1P	152973-97-2P	152973-98-3P
	152973-99-4P	152974-00-0P	152974-01-1P	152974-02-2P	152974-03-3P
	152974-04-4P	152974-05-5P	153006-95-2P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of, as squalene synthase inhibitor)

IT 590-28-3, Potassium cyanate

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction with amine, in prepn. of phenoxyalkylamine derivs. as drugs)

IT Respiration (animal)
 (effect of indole and phenyl compds. related to 5-hydroxytryptamine on)

IT Blood pressure
 (effect of phenyl and indole compds. related to 3-(2-aminoethyl)indol-5-ol on)

IT Pyruvic acid, [5-(benzyloxy)-2-nitrophenyl]-, sodium salt
 (pharmacology of)

IT **103-90-2**, Acetanilide, 4'-hydroxy- 1215-59-4, Indole,
 5-(benzyloxy)- 2581-34-2, m-Cresol, 4-nitro- 3471-32-7, Hydrazine,
 (p-methoxyphenyl)- 5354-81-4, Benzenediazosulfonic acid, p-methoxy-,
 sodium salt 5367-32-8, Anisole, 3-methyl-4-nitro- 6373-46-2, Aniline,
 p-(benzyloxy)- 6640-09-1, Indole-2-carboxylic acid, 5-(benzyloxy)-
 76869-06-2, Indole, 2-phenyl-3-piperidinomethyl- 100869-83-8, Indole,
 2-methyl-3-pyrrol-1-ylmethyl- 100875-20-5, Indole, 3-
 (diethylaminomethyl)-2-methyl- 101103-83-7, Indole, 5-chloro-2-methyl-3-
 piperidinomethyl- 101111-95-9, Indole, 2,5-dimethyl-3-pyrrol-1-ylmethyl-
 101274-86-6, Indole, 2,5-dimethyl-3-piperidinomethyl- 116956-55-9,
 Pyruvic acid, (5-methoxy-2-nitrophenyl)-, sodium salt 132594-55-9,
 Indole, 3-(dimethylaminomethyl)-2,5-dimethyl-
 (pharmacology of)

=> d 112 49 all

L12 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1979:413356 CAPLUS

DN 91:13356

TI Quantitative measurement of the **vascular** changes produced by UV radiation and carrageenin using the guinea pig ear as the site of inflammation

AU Woodward, D. F.; Owen, D. A. A.

CS Res. Inst., Smith Kline and French Lab., Ltd., Welwyn Garden City/Herts., UK


SO Journal of Pharmacological Methods (1979), 2(1), 35-42
 CODEN: JPMED9; ISSN: 0160-5402

DT Journal

LA English

CC 1-1 (Pharmacodynamics)
 Section cross-reference(s): 8

GI



AB The inflammatory response of guinea pig ears to uv radiation or carrageenin [9000-07-1] was localized permitting sep. quant. measurement of erythema, **vascular** permeability, and edema. The intensity of erythema was detd. by measuring skin temp. changes. **Vascular** permeability changes were detd. by measuring extravascular albumin content, and edema was detd. by changes in ear wt. The time course of the inflammatory response was monitored by repeated detns. of ear temp., permitting the identification of primary-phase and second-phase inflammation. Indomethacin (I) [53-86-1] (4 or 16 mg/kg) injected s.c. 30 min before and 4 h after irradiation dose-dependently decreased ear temp. and **vascular** permeability responses; it did not affect edema.

Phenylbutazone [50-33-9] (10 or 50 mg/kg) and aspirin [50-78-2] (200 mg/kg) injected s.c. 30 min before irradiation also decreased ear temperature response. Paracetamol [103-90-2] (100 mg/kg, s.c.) had no effect on ear temperature response to irradiation.

ST inflammation model ear carrageenin UV; indomethacin inflammation model ear
IT Inflammation
(from carrageenin and UV radiation, in guinea pig ear)
IT Inflammation inhibitors
(inflammation from carrageenin and UV radiation in guinea pig ear response to)
IT Ear
(inflammation model from carrageenin and UV radiation in, of guinea pig)
IT Ultraviolet radiation, biological effects
(inflammation model from, in guinea pig ear)
IT 50-33-9, biological studies 50-78-2 53-86-1 103-90-2
RL: BIOL (Biological study)
(inflammation from carrageenin and UV radiation in guinea pig ear response to)
IT 9000-07-1
RL: BIOL (Biological study)
(inflammation model from, in guinea pig ear)

=> d 112 51 all

L12 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1974:201 CAPLUS
DN 80:201
TI Effect of antiinflammatory and antiproteolytic preparations on **vascular** disturbances of the intestines of animals irradiated by supralethal doses
AU Uklonskaya, L. I.; Kudryavtsev, V. D.; Sushkevich, L. N.; Cherkasov, V. F.
CS Res. Inst. Med. Radiol., Obninsk, USSR
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1973), 76(8), 37-9
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian
CC 1-5 (Pharmacodynamics)
AB Butadion (I) [50-33-9] (20 mg/kg/day) decreased the increased **vascular** permeability in the small and large intestines and prolonged the survival of animals when injected i.p. for 3 days into rats irradiated with gamma-rays at 900 or 1000 R. The effects of paracetamol [103-90-2] (60 mg/kg/day), rheopyrine [8064-79-7] (6 mg/kg/day) or trasylol [9004-04-0] (45 I.U./kg/day) plus epsilon-aminocaproic acid [60-32-2] (80 mg/kg/day) were less pronounced.
ST butadion intestine vasculature permeability irradiation; paracetamol intestine vasculature permeability irradiation; rheopyrine intestine vasculature permeability irradiation; trasylol intestine vasculature permeability irradiation; aminocaproate intestine permeability irradiation
IT Blood vessel, toxic chemical and physical damage
Intestine, toxic chemical and physical damage
(from radiation, inflammation inhibitors effect on)
IT Gamma ray, biological effects
(on blood vessel permeability, inflammation inhibitors in relation to)
IT Inflammation inhibitors
(**vascular** permeability from radiation response to)
IT 50-33-9 60-32-2 103-90-2 8064-79-7 9087-70-1
RL: BIOL (Biological study)
(**vascular** permeability from radiation response to)

=> d 112 40 all

L12 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:400372 CAPLUS
DN 111:372
TI Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
AU Green, K.; Drvota, V.; Vesterqvist, O.
CS Dep. Clin. Chem. Blood Coagulation, Karolinska Hosp., Stockholm, S-104 01, Swed.
SO Prostaglandins (1989), 37(3), 311-15
CODEN: PRGLBA; ISSN: 0090-6980
DT Journal
LA English
CC 1-7 (Pharmacology)
AB The effect of a single dose of 500 mg acetaminophen on the in vivo synthesis of prostacyclin was studied in healthy volunteers by measurements of the urinary excretion of 2,3-dinor-6-keto-PGF1.alpha.. Acetaminophen caused a marked redn. of prostacyclin synthesis for 6-8 h without any obvious effect on the thromboxane synthesis. Thus, acetaminophen may at least theor. be disadvantageous for patients suffering from diseases where prostacyclin-mediated **vascular** defense mechanisms are activated, like myocardial infarction, deep vein thrombosis, and following surgery.
ST acetaminophen prostacyclin formation
IT 54397-85-2, TXB2
RL: BIOL (Biological study)
(acetaminophen decrease of prostacyclin formation in humans in relation to)
IT 35121-78-9, Prostacyclin
RL: FORM (Formation, nonpreparative)
(formation of, acetaminophen decrease of, in humans)
IT **103-90-2**, Acetaminophen
RL: BIOL (Biological study)
(prostacyclin formation decrease by, in humans)

=> d 112 22 all

L12 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:789314 CAPLUS
DN 134:235500
TI Circulating soluble **vascular** adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease
AU Kurkijarvi, Riikka; Yegutkin, Gennady G.; Gunson, Bridget K.; Jalkanen, Sirpa; Salmi, Marko; Adams, David H.
CS Liver Research Laboratories, MRC Centre for Immune Regulation at the University of Birmingham, Birmingham, UK.
SO Gastroenterology (2000), 119(4), 1096-1103
CODEN: GASTAB; ISSN: 0016-5085
PB W. B. Saunders Co.
DT Journal
LA English
CC 14-7 (Mammalian Pathological Biochemistry)
AB **Vascular** adhesion protein 1 (VAP-1) is an endothelial glycoprotein that supports adhesion of lymphocytes to hepatic endothelium and has sequence homol. with semicarbazide-sensitive amine oxidases (SSAOs). Whether sol. VAP-1 (sVAP-1) displays SSAO activity and thereby accounts for increased monoamine oxidase activity in the serum of patients with liver diseases was investigated. sVAP-1 concn. and SSAO activity were measured in peripheral, hepatic, and portal blood and in bile from patients with liver disease and in peripheral blood of control subjects,

using ELISA and enzymic assays. SVAP-1 concn. and SSAO activity were significantly increased in chronic liver diseases compared with healthy controls but not in massive necrosis caused by paracetamol poisoning. SVAP-1 correlated with serum transaminase and bilirubin but not with creatinine. In 5 paired samples, sVAP-1 concn. was higher in hepatic than in portal vein and was not detected in bile. There was a highly significant correlation between serum sVAP-1 and SSAO activity in normal subjects, patients with acute liver failure, and those with chronic liver disease. When serum was depleted of sVAP-1 by immunoaffinity chromatog., SSAO activity was eliminated. marker. SVAP-1 levels are increased in chronic liver disease, and sVAP-1 is likely derived from the liver. Serum sVAP-1 displays SSAO activity and accounts for most of the monoamine oxidase activity in human serum.

- ST **vascular** adhesion protein 1 blood liver disease monoamine oxidase
- IT Cirrhosis
- Hepatitis
 - (alc.; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Hepatitis
 - (autoimmune; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Biliary tract
 - (cholangioma; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Liver, disease
 - (chronic; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Bile
- Biomarkers (biological responses)
- Hepatitis
 - (circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Intestine, neoplasm
 - (colorectal, metastasis, to liver; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Cirrhosis
 - (cryptogenic; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Biliary tract
 - (disease, chronic; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Liver, disease
 - (failure; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Liver, neoplasm
 - (hepatoma; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)
- IT Liver, disease
 - (inflammation; circulating sol. **vascular** adhesion protein 1 (sVAP-1) accounts for increased serum monoamine oxidase activity in chronic liver diseases in humans)

IT Transplant and Transplantation
(liver; circulating sol. **vascular** adhesion protein 1 (sVAP-1)
accounts for increased serum monoamine oxidase activity in chronic
liver diseases in humans)

IT Liver, neoplasm
(metastasis, from colorectal cancer; circulating sol. **vascular**
adhesion protein 1 (sVAP-1) accounts for increased serum monoamine
oxidase activity in chronic liver diseases in humans)

IT Liver, disease
(necrosis, paracetamol poisoning; circulating sol. **vascular**
adhesion protein 1 (sVAP-1) accounts for increased serum monoamine
oxidase activity in chronic liver diseases in humans)

IT Blood serum
(peripheral, hepatic, and portal; circulating sol. **vascular**
adhesion protein 1 (sVAP-1) accounts for increased serum monoamine
oxidase activity in chronic liver diseases in humans)

IT Biliary tract
(primary biliary cirrhosis; circulating sol. **vascular**
adhesion protein 1 (sVAP-1) accounts for increased serum monoamine
oxidase activity in chronic liver diseases in humans)

IT Liver
(sinusoid, endothelium; circulating sol. **vascular** adhesion
protein 1 (sVAP-1) accounts for increased serum monoamine oxidase
activity in chronic liver diseases in humans)

IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BOC (Biological
occurrence); BSU (Biological study, unclassified); BIOL (Biological
study); OCCU (Occurrence)
(sol. **vascular** adhesion protein 1; circulating sol.
vascular adhesion protein 1 (sVAP-1) accounts for increased
serum monoamine oxidase activity in chronic liver diseases in humans)

IT Liver
(transplant; circulating sol. **vascular** adhesion protein 1
(sVAP-1) accounts for increased serum monoamine oxidase activity in
chronic liver diseases in humans)

IT Liver, disease
(**vascular**; circulating sol. **vascular** adhesion
protein 1 (sVAP-1) accounts for increased serum monoamine oxidase
activity in chronic liver diseases in humans)

IT Poisoning, biological
(with paracetamol; circulating sol. **vascular** adhesion protein
1 (sVAP-1) accounts for increased serum monoamine oxidase activity in
chronic liver diseases in humans)

IT 9000-97-9, Aspartate aminotransferase 9001-66-5, Monoamine oxidase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(circulating sol. **vascular** adhesion protein 1 (sVAP-1)
accounts for increased serum monoamine oxidase activity in chronic
liver diseases in humans)

IT 60-27-5, Creatinine 635-65-4, Bilirubin, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)
(circulating sol. **vascular** adhesion protein 1 (sVAP-1)
accounts for increased serum monoamine oxidase activity in chronic
liver diseases in humans)

IT 103-90-2, Paracetamol
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(poisoning; circulating sol. **vascular** adhesion protein 1
(sVAP-1) accounts for increased serum monoamine oxidase activity in
chronic liver diseases in humans)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Adams, D; Hepatology 1992, V16, P810 MEDLINE
- (2) Adams, D; Hepatology 1994, V19, P588 MEDLINE
- (3) Adams, D; Transplantation 1993, V55, P83 MEDLINE
- (4) Bloom, S; Gut 1995, V36, P604 MEDLINE
- (5) Bono, P; J Immunol 1998, V160, P5563 CAPLUS
- (6) Boomsma, F; Cardiovasc Res 1997, V33, P387 MEDLINE
- (7) Borthakur, P; Indian J Med Res 1973, V61, P1165 MEDLINE
- (8) Buckley, C; In physiology of inflammation P285
- (9) Colombato, L; Hepatology 1992, V15, P323 MEDLINE
- (10) Finkel, T; Curr Opin Cell Biol 1998, V10, P248 CAPLUS
- (11) Fowler, C; Biochem Pharmacol 1981, V30, P3329 CAPLUS
- (12) Gearing, A; Immunol Today 1993, V14, P506 CAPLUS
- (13) Gopfert, T; J Cell Physiol 1996, V168, P354 MEDLINE
- (14) Gressner, A; J Clin Chem Clin Biochem 1980, V18, P921 CAPLUS
- (15) Gressner, A; J Clin Chem Clin Biochem 1982, V20, P509 MEDLINE
- (16) Ito, K; Digestion 1971, V4, P49 MEDLINE
- (17) Jaeschke, H; Am J Physiol 1997, V273, PG602 CAPLUS
- (18) Jaeschke, H; Hepatology 1997, V25, P252 MEDLINE
- (19) Kurkijarvi, R; J Immunol 1998, V161, P1549 CAPLUS
- (20) Lalor, P; J Clin Mol Pathol 1999, V52, P214 MEDLINE
- (21) Lim, A; J Hepatol 1995, V22, P416 MEDLINE
- (22) Lyles, G; Int J Biochem Cell Biol 1996, V28, P259 CAPLUS
- (23) McEwen, C; J Lab Clin Med 1967, V70, P36 CAPLUS
- (24) McNab, G; Gastroenterology 1996, V110, P522 CAPLUS
- (25) Nakano, H; Clin Chim Acta 1978, V88, P315 CAPLUS
- (26) Petermann, H; J Hepatol 1998, V28, P461 CAPLUS
- (27) Pigott, R; Biochem Biophys Res Commun 1992, V187, P584 CAPLUS
- (28) Salmi, M; Adv Immunol 1997, V64, P139 CAPLUS
- (29) Salmi, M; Am J Physiol 1998, V274, PG1 CAPLUS
- (30) Salmi, M; J Exp Med 1993, V178, P2255 CAPLUS
- (31) Salmi, M; J Exp Med 1996, V183, P569 CAPLUS
- (32) Salmi, M; J Exp Med 1997, V186, P598
- (33) Salmi, M; J Immunol 1998, V160, P5629 CAPLUS
- (34) Salmi, M; Science 1992, V257, P1407 CAPLUS
- (35) Smith, D; J Exp Med 1998, V188, P17 CAPLUS
- (36) Smith, D; J Exp Med 1998, V188, P17 CAPLUS
- (37) Steinhoff, G; Am J Pathol 1993, V142, P481 CAPLUS
- (38) Wong, J; J Clin Invest 1997, V99, P2782 CAPLUS
- (39) Yoong, K; J Immunol 1998, V160, P3978 CAPLUS
- (40) Yu, P; Biochem Pharmacol 1994, V47, P1055 CAPLUS
- (41) Yu, P; J Neural Transm 1994, V41(Suppl), P397

=> d 112 21 all

L12 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:82583 CAPLUS
 DN 134:295096
 TI Anti-microinflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: A novel mechanism for NSAID and n-3 PUFA therapeutic actions
 AU Serhan, Charles N.; Clish, C. B.; Brannon, J.; Colgan, S. P.; Gronert, K.; Chiang, N.
 CS Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
 SO Journal of Physiology and Pharmacology (2000), 51(4, Pt. 1), 643-654
 CODEN: JPHPEI; ISSN: 0867-5910
 PB Polish Physiological Society
 DT Journal
 LA English
 CC 18-5 (Animal Nutrition)

AB Aspirin (ASA) inhibits prostaglandin (PG) biosynthesis and via acetylation of cyclooxygenase 2 (COX-2) it leads to bioactive lipoxins epimeric at carbon 15 (15-epi-LX, also termed aspirin-triggered lipoxins or ATL). Inflammatory exudates from mice treated with n-3 polyunsatd. fatty acids (PUFA) and ASA contain an array of bioactive lipids. Human endothelial cells, both HUVEC and microvascular, with upregulated COX-2 and treated with ASA convert C20:5n-3 to 18R-hydroxyeicosapentaenoic acid (HEPE) and 15R-HEPE. Human polymorphonuclear neutrophils (PMN) activated with serum-treated zymosan (STZ) utilize these R-HEPE compds. to produce trihydroxy mediators, including the 5-series 15R-LX and 5,12,18R-triHEPE. These novel products are potent inhibitors of human PMN transendothelial migration and PMN infiltration into dorsal air pouches in vivo. In addn. to ASA, both acetaminophen and indomethacin also permit 18R-HEPE and 15R-HEPE generation with recombinant human COX-2 and n-5 and n-9 oxygenations of other fatty acids that act on leukocytes, blood platelets, and endothelial cells. These data establish new transcellular routes for producing arrays of lipid mediators via COX-2/nonsteroidal anti-inflammatory drugs (NSAID) and cell-cell interactions that impact microinflammation. They provide novel mechanism(s) that could underlie the many reported therapeutic benefits of n-3 dietary supplements of interest in inflammation, cancer, and **vascular** disorders.

ST nutrition fatty acid aspirin acetaminophen indomethacin cyclooxygenase prostaglandin inflammation

IT Nutrition, animal
(dietary n-3 fatty acids and aspirin, acetaminophen and indomethacin effects on anti-microinflammatory prostaglandin metabolites produced by cyclooxygenase-2 and transcellular processing)

IT Prostaglandins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(dietary n-3 fatty acids and aspirin, acetaminophen and indomethacin effects on anti-microinflammatory prostaglandin metabolites produced by cyclooxygenase-2 and transcellular processing)

IT Fatty acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; dietary n-3 fatty acids and aspirin, acetaminophen and indomethacin effects on anti-microinflammatory prostaglandin metabolites produced by cyclooxygenase-2 and transcellular processing)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 103-90-2, Acetaminophen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dietary n-3 fatty acids and aspirin, acetaminophen and indomethacin effects on anti-microinflammatory prostaglandin metabolites produced by cyclooxygenase-2 and transcellular processing)

IT 60-33-3, Linoleic acid, biological studies 10417-94-4 18104-45-5, 13-Hode 39391-18-9, Cyclooxygenase 73347-43-0, 11(R)-HETE 83603-31-0, 15(R)-HETE 95851-20-0 98524-19-7 104758-12-5 109430-11-7 312516-11-3 312516-12-4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(dietary n-3 fatty acids and aspirin, acetaminophen and indomethacin effects on anti-microinflammatory prostaglandin metabolites produced by cyclooxygenase-2 and transcellular processing)

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; Proceedings of the AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids 1987
- (2) Anon; Robbins Pathologic Basis of Disease. 6th ed 1999
- (3) Anon; n-3 Fatty Acids and Vascular Disease 1993
- (4) Bandeira-Melo, C; J Immunol 2000, V164, P1029 CAPLUS
- (5) Billman, G; Circulation 1999, V99, P2452 CAPLUS
- (6) Buchanan, M; Prostaglandins Leukot Essent Fatty Acids 1998, V58, P339

CAPLUS

- (7) Capdevila, J; J Biol Chem 1996, V271, P22663 CAPLUS
- (8) Chiang, N; J Clin Invest 1999, V104, P309 CAPLUS
- (9) Chiang, N; J Pharmacol Exp Ther 1998, V287, P779 CAPLUS
- (10) Claria, J; Proc Nat Acad Sci USA 1995, V92, P9475 CAPLUS
- (11) Clish, C; Proc Natl Acad Sci USA 1999, V96, P8247 CAPLUS
- (12) Cronstein, B; Proc Natl Acad Sci USA 1992, V89, P9991 CAPLUS
- (13) George, H; Protein Expres Purif 1996, V7, P19 CAPLUS
- (14) Gilroy, D; Nature Med 1999, V5, P698 CAPLUS
- (15) Gronert, K; Eicosanoid Protocols 1999, P119 CAPLUS
- (16) Hachicha, M; J Exp Med 1999, V189, P1923 CAPLUS
- (17) Herschman, H; Trends Cardiovasc Med 1998, V8, P145 CAPLUS
- (18) Hill, D; Biochim Biophys Acta 1999, V1437, P63 CAPLUS
- (19) Iigo, M; Br J Cancer 1997, V75, P650 CAPLUS
- (20) Laneuville, O; J Biol Chem 1995, V270, P19330 CAPLUS
- (21) Lee, T; J Biol Chem 1984, V259, P2383 CAPLUS
- (22) Levy, G; FASEB J 1997, V11, P234 CAPLUS
- (23) Marcus, A; Inflammation: Basic Principles and Clinical Correlates 1999, P77
- (24) Needleman, P; J Rheumatol 1997, V24(Suppl 49), P6
- (25) Node, K; Science 1999, V285, P1276 CAPLUS
- (26) Otto, J; Molecular Biology of the Arachidonate Cascade 1995, P139 CAPLUS
- (27) Powell, W; Biochim Biophys Acta 1985, V835, P201 CAPLUS
- (28) Ruettinger, R; J Biol Chem 1981, V256, P5728 CAPLUS
- (29) Serhan, C; Am J Respir Crit Care Med 2000, V161, PS95 MEDLINE
- (30) Serhan, C; Biochemistry 1995, V34, P14609 CAPLUS
- (31) Serhan, C; Inflammation: Basic Principles and Clinical Correlates 1999, P373
- (32) Simopoulos, A; J Am Coll Nutr 1999, V18, P487 MEDLINE
- (33) Weissmann, G; Sci Am 1991, V264, P84 CAPLUS
- (34) Xiao, G; Biochemistry 1997, V36, P1836 CAPLUS
- (35) Yokomizo, T; Nature 1997, V387, P620 CAPLUS

```
=> s cox-2
      11638 COX
      7800245 2
L13      5160 COX-2
          (COX(W)2)
```

```
=> d is
'IS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
          SCAN must be entered on the same line as the DISPLAY,
```

e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels

IMAX ----- MAX, indented with text labels

ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram

HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram

FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):his
'HIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

IND ----- Indexing data

IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE

PATS ----- PI, SO

SAM ----- CC, SX, TI, ST, IT

SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,